Won Sohn, Young-Sun Lee, Soon Sun Kim, Jung Hee Kim, Young-Joo Jin, Gi-Ae Kim, Pil Soo Sung, Jeong-Ju Yoo, Young Chang, Eun Joo Lee, Hye Won Lee, Miyoung Choi, Su Jong Yu, Young Kul Jung, Byoung Kuk Jang, on behalf of The Korean Association for the Study of the Liver (KASL)
Clin Mol Hepatol 2025;31(Suppl):S1-S31. Published online February 19, 2025
Differential Infiltration of T-Cell Populations in Tumor and Liver Tissues Predicts Recurrence-Free Survival in Surgically Resected Hepatocellular Carcinoma Eun Ji Jang, Ho Joong Choi, Young Kyoung You, Deok Hwa Seo, Mi Hyun Kwon, Keungmo Yang, Jaejun Lee, Jeong Won Jang, Seung Kew Yoon, Ji Won Han, Pil Soo Sung Cancers.2025; 17(9): 1548. CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease, Recent Revision of Terminology and Its Implications Hyo Young Lee, Eileen L. Yoon The Korean Journal of Gastroenterology.2025; 85(2): 126. CrossRef
Advances in identifying risk factors of metabolic dysfunction-associated alcohol-related liver disease Rui-Qi Ye, Yi-Fan Chen, Chang Ma, Xi Cheng, Wei Guo, Sha Li Biomedicine & Pharmacotherapy.2025; 188: 118191. CrossRef
A Case Report of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) with Improved Cardiometabolic Risk Factors Following Treatment with Saenggangunbi-tang Eun Kyung Lee, Min Jeong Park, Youngchul Kim, Jang-Hoon Lee The Journal of Internal Korean Medicine.2025; 46(2): 303. CrossRef
Food Nutrients and Bioactive Compounds for Managing Metabolic Dysfunction-Associated Steatotic Liver Disease: A Comprehensive Review Erdenetsogt Dungubat, Kohei Fujikura, Masahiko Kuroda, Toshio Fukusato, Yoshihisa Takahashi Nutrients.2025; 17(13): 2211. CrossRef
Associations between steatotic liver disease subtypes and incident atrial fibrillation in young adults: a nationwide cohort study Jeayeon Park, Goh Eun Chung, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Kyungdo Han, Eun Ju Cho Cardiovascular Diabetology.2025;[Epub] CrossRef
Second-line antidiabetic drugs: friend or foe of the liver Jiwon Yang, Gunho Kim, Ju Hyun Shim, Jihyun An Journal of Liver Cancer.2025; 25(2): 187. CrossRef
Extrahepatic manifestation of metabolic dysfunction-associated steatotic liver disease Anoushka Shenoy, Aijaz Ahmed, Donghee Kim Metabolism and Target Organ Damage.2025;[Epub] CrossRef
2025 Clinical Practice Guidelines for Diabetes: Management of Metabolic Dysfunction-Associated Steatotic Liver Disease Jaehyun Bae The Journal of Korean Diabetes.2025; 26(3): 172. CrossRef
Paired snRNA-seq and scRNA-seq analysis of MASLD patients to identify early-stage markers for disease progression Suebin Park, Su-Hyeon Lee, Se-eun Han, Beom Kyung Kim, Byungjin Hwang Hepatology Communications.2025;[Epub] CrossRef
Sex Hormones and Metabolic Dysfunction-Associated Steatotic Liver Disease Ralf Weiskirchen, Amedeo Lonardo International Journal of Molecular Sciences.2025; 26(19): 9594. CrossRef
Discovery of ultrasound-derived fat fraction as a non-invasive tool for MASLD diagnosis Huiru Jin, Mengfan Jiao, Chengxiao Yu, Tingting Ren, Qingling Chen, Zixing Dai, Erfu Xie, Longfeng Jiang, Yuwen Li European Journal of Medical Research.2025;[Epub] CrossRef
Risk of Esophageal and Gastric Cancer by Histologic Subtype in Steatotic Liver Disease: A UK Biobank Study Donghoon Kang, Ji Won Han, Kenneth R. Muir, Artitaya Lophatananon, Jongin Lee Cancers.2025; 17(21): 3416. CrossRef
Background/Aims Direct-acting antivirals (DAAs) effectively eradicate hepatitis C virus. This study investigated whether metabolic dysfunction influences the likelihood of fibrosis regression after DAA treatment in patients with chronic hepatitis C (CHC).
Methods This multicenter, retrospective study included 8,819 patients diagnosed with CHC who were treated with DAAs and achieved a sustained virological response (SVR) between January 2014 and December 2022. Fibrosis regression was defined as a 20% reduction in noninvasive surrogates for liver fibrosis, such as liver stiffness (LS) measured by vibration-controlled transient elastography (VCTE) and the fibrosis-4 (FIB-4) score. Hypercholesterolemia (h-TC) was defined as >200 mg/dL.
Results The median age of the study population was 59.6 years, with a predominance of male patients (n=4,713, 57.3%). Genotypes 1, 2, and others were confirmed in 3,872 (46.2%), 3,487 (41.6%), and 1,024 (12.2%) patients, respectively. Diabetes mellitus (DM) was present in 1,442 (17.2%) patients and the median LS was 7.50 kPa (interquartile range, 5.30–12.50). Multivariate analysis revealed that the presence of DM and pre-DAA h-TC were independently associated with a decreased probability of fibrosis regression by VCTE. Additionally, pre-DAA h-TC was independently associated with a decreased probability of fibrosis regression by the FIB-4.
Conclusions Metabolic dysfunction has an unfavorable influence on fibrosis regression in patients with CHC who achieve SVR after DAA treatment.
Citations
Citations to this article as recorded by
Editorial: Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral‐Induced Cure of Hepatitis C Virus Infection—Authors' Reply Yu‐Ping Chang, Jia‐Horng Kao, Chen‐Hua Liu Alimentary Pharmacology & Therapeutics.2025; 61(9): 1553. CrossRef
Epidemiologic Characteristics of Chronic Hepatitis B and Coinfections with Hepatitis C Virus or Human Immunodeficiency Virus in South Korea: A Nationwide Claims-Based Study Using the Korean Health Insurance Review and Assessment Service Database Hyunwoo Oh, Won Sohn, Na Ryung Choi, Hyo Young Lee, Yeonjae Kim, Seung Woo Nam, Jae Yoon Jeong Pathogens.2025; 14(7): 715. CrossRef
Background/Aims Bariatric intervention has been reported to be an effective way to improve metabolic dysfunction-associated steatotic liver disease (MASLD) in obese individuals. The current systemic review aimed to assess the changes in MRI-determined hepatic proton density fat fraction (MRI-PDFF) and nonalcoholic fatty liver disease activity score (NAS) after bariatric surgery or intragastric balloon/gastric banding in MASLD patients with obesity.
Methods We searched various databases including PubMed, OVID Medline, EMBASE, and Cochrane Library. Primary outcomes were the changes in intrahepatic fat on MRI-PDFF and histologic features of metabolic dysfunction-associated steatohepatitis (MASH).
Results Thirty studies with a total of 3,134 patients were selected for meta-analysis. Bariatric intervention significantly reduced BMI (ratio of means, 0.79) and showed 72% reduction of intrahepatic fat on MRI-PDFF at 6 months after bariatric intervention (ratio of means, 0.28). Eight studies revealed that NAS was reduced by 60% at 3–6 months compared to baseline, 40% at 12–24 months, and 50% at 36–60 months. Nineteen studies revealed that the proportion of patients with steatosis decreased by 44% at 3–6 months, 37% at 12–24 months, and 29% at 36–60 months; lobular inflammation by 36% at 12–24 months and 51% at 36–60 months; ballooning degeneration by 38% at 12–24 months; significant fibrosis (≥F2) by 18% at 12–24 months and by 17% at 36–60 months after intervention.
Conclusions Bariatric intervention significantly improved MRI-PDFF and histologic features of MASH in patients with obesity. Bariatric intervention might be the effective alternative treatment option for patients with MASLD who do not respond to lifestyle modification or medical treatment.
Citations
Citations to this article as recorded by
Serial changes in metabolic dysfunction-associated steatotic liver disease after sleeve gastrectomy and their associations with abdominal adiposity: a prospective cohort study Chung-Yi Yang, Jian-Han Chen, Chung-Yen Chen, Cheng-Yi Kao, Shiu-Feng Huang, Wen-Yu Chang, Hung-Pin Tu, Jee-Fu Huang, Ming-Lung Yu, Chi-Ming Tai Surgery for Obesity and Related Diseases.2025; 21(5): 537. CrossRef
Bariatric nutrition and evaluation of the metabolic surgical patient: Update to the 2022 Obesity Medicine Association (OMA) bariatric surgery, gastrointestinal hormones, and the microbiome clinical practice statement (CPS) Sue Benson-Davies, Kirsten Frederiksen, Rutuja Patel Obesity Pillars.2025; 13: 100154. CrossRef
Letter to the editor on “Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis” Xiao-Song Li, Xi-Ping Shen, Hang Li Clinical and Molecular Hepatology.2025; 31(1): e15. CrossRef
Correspondence to letter to the editor on “Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis” Yuri Cho, Dae Won Jun Clinical and Molecular Hepatology.2025; 31(1): e103. CrossRef
Glucagon like peptide-1 receptor agonists as a promising therapeutic option of metabolic dysfunction associated steatotic liver disease and obesity: hitting two targets with one shot Eda Kaya, Wing-Kin Syn, Paul Manka Current Opinion in Gastroenterology.2025; 41(3): 104. CrossRef
Perioperative Screening for Metabolic Dysfunction Associated Steatotic Liver Disease in People Undergoing Bariatric Surgery: A Pilot Study David M. Williams, Thinzar Min, Andrew Beamish, Jeffrey W. Stephens Obesity Surgery.2025; 35(5): 1963. CrossRef
Impact of Severity of Metabolism-Related Fatty Liver Disease Based on Pathologic Grading on Outcomes after Sleeve Gastrectomy 云飞 曲 Journal of Clinical Personalized Medicine.2025; 04(02): 826. CrossRef
Cambios biométricos y metabólicos a un año de seguimiento en pacientes con obesidad e hígado graso sometidos a gastroplastia endoscópica en manga-EndoSleeve (método Apollo) Diego Schwarzstein, Lissette Batista, Patricia Gonçalves, Luis Yip, Leoniana Bustillos, Mar Bacardit, Josep Merlo Revista de la Sociedad Española de Cirugía de Obesidad y Metabólica y de la Sociedad Española para el Estudio de la Obesidad.2025;[Epub] CrossRef
Liver and obesity: a narrative review Amedeo Lonardo, Ralf Weiskirchen Exploration of Medicine.2025;[Epub] CrossRef
Incretins and MASLD: at the Crossroads of Endocrine and Hepatic Disorders Marwin A. Farrugia, Enzo Pini, Albert Tran, Nicolas Chevalier, Rodolphe Anty, Philippe Gual Current Obesity Reports.2025;[Epub] CrossRef
Comparative effectiveness of tirzepatide versus bariatric metabolic surgery in adults with metabolic-associated steatotic liver disease and obesity: a multi-institutional propensity score-matched study Jheng-Yan Wu, Yu-Min Lin, Wan-Hsuan Hsu, Ting-Hui Liu, Ya-Wen Tsai, Po-Yu Huang, Min-Hsiang Chuang, Tsung Yu, Chih-Cheng Lai Hepatology International.2025; 19(5): 1087. CrossRef
Exploring the role of xanthine oxidase and aldehyde oxidase in metabolic dysfunction-associated steatotic liver disease (MASLD) Neha Gupta, Kavita Singh Journal of Molecular Histology.2025;[Epub] CrossRef
Diabetes mellitus as a multisystem disease: understanding subtypes, complications, and the link with steatotic liver diseases in humans Anna Giannakogeorgou, Michael Roden, Kalliopi Pafili Hormones.2025;[Epub] CrossRef
Duodenal mucosal ablation: An emerging therapeutic concept for metabolic dysfunction-associated fatty liver disease Cornelius J Fernandez, Sweekruti Jena, Vijaya Lakshmi, Joseph M Pappachan World Journal of Gastroenterology.2025;[Epub] CrossRef
Multiparametric MRI Evaluation of Liver Fat and Iron after Glucagon-like Peptide-1 Receptor and Glucagon Receptor Dual-Agonist Treatment in a High-Fat Diet–induced Mouse Model Huimin Xia, Yuqin Min, Yuhua Wang, Siyu Gao, Hailing Wang, Fuhua Yan, Ruixin Liu, Jiqiu Wang, Xuejiang Gu, Tingting Bo Radiology.2025;[Epub] CrossRef
Cirrhotic Cardiomyopathy: Bridging Hepatic and Cardiac Pathophysiology in the Modern Era Dragoș Lupu, Camelia Cornelia Scârneciu, Diana Țînț, Cristina Tudoran Journal of Clinical Medicine.2025; 14(17): 5993. CrossRef
ISImatsuda as a potential predictor of metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus Jing Liu, Yueqiu Wang, Xinghang Zhou, Zaixin Wen, Yu Chen, Yiqiong Sun, Shuaiying Su, Weiwei Lin, Ruiting Shen, Xiaoyu Sun, Hongru Li, Xia Yu, Mingchen Zhang Frontiers in Medicine.2025;[Epub] CrossRef
Connecting the Dots: Hepatic Steatosis as a Central Player in the Choreography of the Liver-Cardiovascular-Kidney-Metabolic Syndrome Richard H. Goodheart, Oyekoya T. Ayonrinde Heart, Lung and Circulation.2025; 34(10): 1050. CrossRef
Prospective evaluation of a structured group education programme for patients with metabolic dysfunction-associated steatotic liver disease (MASLD) Thomas Crame, Rachel Howarth, Elizabeth Johnstone, Hollie Smith, Stuart McPherson, Kate Hallsworth Frontline Gastroenterology.2025; : flgastro-2025-103280. CrossRef
Endoscopic Bariatric Therapies for Metabolic Dysfunction-Associated Steatotic Liver Disease: Mechanistic Insights and Metabolic Implications Wissam Ghusn, Mira Sridharan, Rachel Fromer, Muhammet Ozdemir, Madeleine G. Haff, Eric J. Vargas Biomedicines.2025; 13(10): 2437. CrossRef
Metabolic Dysfunction–Associated Steatotic Liver Disease in Adults Herbert Tilg, Salvatore Petta, Norbert Stefan, Giovanni Targher JAMA.2025;[Epub] CrossRef
Emerging mechanisms of non-alcoholic steatohepatitis and novel drug therapies Hao CHEN, Yang ZHOU, Haiping HAO, Jing XIONG Chinese Journal of Natural Medicines.2024; 22(8): 724. CrossRef
Weight Loss After Sleeve Gastrectomy According to Metabolic Dysfunction-Associated Steatotic Liver Disease Stage in Patients with Obesity: A Liver Biopsy-Based Prospective Study José Ignacio Martínez-Montoro, Isabel Arranz-Salas, Carolina Gutiérrez-Repiso, Ana Sánchez-García, Luis Ocaña-Wilhelmi, José M. Pinazo-Bandera, Diego Fernández-García, Araceli Muñoz-Garach, Dieter Morales-García, Miren García-Cortés, Eduardo García-Fuente Nutrients.2024; 16(22): 3857. CrossRef
Do Seon Song, Hee Yeon Kim, Young Kul Jung, Tae Hyung Kim, Hyung Joon Yim, Eileen L Yoon, Ki Tae Suk, Jeong-ju Yoo, Sang Gyune Kim, Moon Young Kim, Young Chang, Soung Won Jeong, Jae Young Jang, Sung-Eun Kim, Jung-Hee Kim, Jung Gil Park, Won Kim, Jin Mo Yang, Dong Joon Kim, Korean Acute-on-Chronic Liver Failure (KACLiF) study group, Ashok Kumar Choudhury, Vinod Arora, Shiv Kumar Sarin, APASL ACLF Research Consortium (AARC) for APASL ACLF working party
Clin Mol Hepatol 2024;30(3):388-405. Published online April 11, 2024
Background/Aims Quick sequential organ failure assessment (qSOFA) is believed to identify patients at risk of poor outcomes in those with suspected infection. We aimed to evaluate the ability of modified qSOFA (m-qSOFA) to identify high-risk patients among those with acutely deteriorated chronic liver disease (CLD), especially those with acute-onchronic liver failure (ACLF).
Methods We used data from both the Korean Acute-on-Chronic Liver Failure (KACLiF) and the Asian Pacific Association for the Study of the Liver ACLF Research Consortium (AARC) cohorts. qSOFA was modified by replacing the Glasgow Coma Scale with hepatic encephalopathy, and an m-qSOFA ≥2 was considered high.
Results Patients with high m-qSOFA had a significantly lower 1-month transplant-free survival (TFS) in both cohorts and higher organ failure development in KACLiF than those with low m-qSOFA (Ps<0.05). Subgroup analysis by ACLF showed that patients with high m-qSOFA had lower TFS than those with low m-qSOFA. m-qSOFA was an independent prognostic factor (hazard ratios, HR=2.604, 95% confidence interval, CI 1.353–5.013, P=0.004 in KACLiF and HR=1.904, 95% CI 1.484– 2.442, P<0.001 in AARC). The patients with low m-qSOFA at baseline but high m-qSOFA on day 7 had a significantly lower 1-month TFS than those with high m-qSOFA at baseline but low m-qSOFA on day 7 (52.6% vs. 89.4%, P<0.001 in KACLiF and 26.9% vs. 61.5%, P<0.001 in AARC).
Conclusions Baseline and dynamic changes in m-qSOFA may identify patients with a high risk of developing organ failure and short-term mortality among CLD patients with acute deterioration.
Citations
Citations to this article as recorded by
Emergency living donor liver transplantation Jongman Kim Annals of Liver Transplantation.2025; 5(1): 27. CrossRef
Oral Branched-Chain Amino Acids as a Cost-Effective Option for Managing Hepatic Encephalopathy Hankil Lee, Sang Hoon Ahn, Beom Kyung Kim Yonsei Medical Journal.2025; 66(11): 713. CrossRef
Living versus deceased donor liver transplantation in highly urgent patients using Korean national data Jongman Kim, Sang Jin Kim, Kyunga Kim, YoungRok Choi, Geun Hong, Jun Yong Park, Young Seok Han, Nam-Joon Yi, Soon-Young Kim, Jung-Bun Park, Youngwon Hwang, Dong-Hwan Jung Annals of Liver Transplantation.2025; 5(2): 115. CrossRef
Predicting risk factors for waiting mortality in adult emergent living donor liver transplantation based on Korean national data Sang Jin Kim, Jongman Kim, Kyunga Kim, Soon-Young Kim, Jung-Bun Park, Youngwon Hwang, Dong-Hwan Jung Annals of Liver Transplantation.2025; 5(2): 107. CrossRef
Correspondence to editorial on “Dynamic analysis of acute deterioration in chronic liver disease patients using modified quick sequential organ failure assessment” Do Seon Song, Dong Joon Kim Clinical and Molecular Hepatology.2024; 30(4): 1012. CrossRef
Modified quick-SOFA score: Can it enhance prognostic assessment for hospitalized patients with chronic liver diseases?: Editorial on “Dynamic analysis of acute deterioration in chronic liver disease patients using modified quick sequential organ failure a Simone Incicco, Salvatore Piano Clinical and Molecular Hepatology.2024; 30(4): 695. CrossRef
Revisiting septic shock in cirrhosis: a call for personalized management Vishnu Girish, Rakhi Maiwall Expert Review of Gastroenterology & Hepatology.2024; 18(12): 795. CrossRef
Background/Aims The histologic status of the immune-tolerant (IT) phase of chronic hepatitis B relative to long-term outcomes is unclear. This study aimed to discover how the serological criteria currently in use correspond to histologic criteria in determining the IT phase and indication for liver biopsy.
Methods Patients in the serological IT phase determined by positive hepatitis B e antigen, hepatitis B virus (HBV) DNA ≥106 IU/mL, and normal or minimally elevated alanine aminotransferase (ALT) ≤60 IU/L, who underwent liver biopsy at three different hospitals were included. The distribution of the histologic IT phase, defined as fibrosis of stage 1 or less and inflammation of grade 1 or less, was compared with that of the serological IT phase. The risk factors for the incidence of liver-related events, such as hepatocellular carcinoma, liver cirrhosis, liver transplantation, and death, were also analyzed.
Results Eighty-two (31.7%) out of 259 clinically suspected IT phase patients belonged to the histologic IT phase. Age over 35, high AST, and low albumin were useful for ruling out the histologic IT phase. Risk factors predicting liver-related events were age and significant fibrosis stage. There was no significant difference in the proportion of histologic IT phase and clinical prognosis between normal ALT and mildly elevated ALT groups. However, even in patients with normal ALT, age was an important factor in predicting the presence of the histologic IT phase.
Conclusions A significant number of patients who belonged to the serological IT phase were not in the histologic IT phase. Patients over 35 years and those with high AST, low albumin, and low HBV DNA levels were more likely to experience poor long-term clinical outcomes. Therefore, additional histologic assessment should be considered.
Citations
Citations to this article as recorded by
Risk of Hepatocellular Carcinoma Decreases After Antiviral Therapy–Induced HBsAg Seroclearance Han Ah. Lee, Hyun Woong Lee, Yeon Seok Seo, Dong Hyun Sinn, Sang Hoon Ahn, Beom Kyung Kim, Seung Up Kim Journal of Gastroenterology and Hepatology.2025; 40(7): 1675. CrossRef
Unraveling Demographic Patterns in Hepatitis B Clinical and Laboratory Profiles: Insights From a Ghanaian Cohort: A Retrospective Study Napoleon Bellua Sam, Saeed Folorunsho Majeed, Adams Dramani Health Science Reports.2025;[Epub] CrossRef
Higher level of HBsAg associated with delayed development of HCC in immune-tolerant patients Tai-Chung Tseng, Tetsuya Hosaka, Mei-Hung Pan, Chun-Jen Liu, Fumitaka Suzuki, Chien-Jen Chen, Tung-Hung Su, Hiromitsu Kumada, Wan-Ting Yang, Hung-Chih Yang, Chen-Hua Liu, Pei-Jer Chen, Hwai-I. Yang, Jia-Horng Kao Hepatology.2025;[Epub] CrossRef
Cost‐Effectiveness of Antiviral Therapy in Patients With High Viremic Indeterminate Phase Chronic Hepatitis B Suk‐Chan Jang, Won‐Mook Choi, Gi‐Ae Kim, Gwang Hyeon Choi, Yun Bin Lee, Dong Hyun Sinn, Hye‐Lin Kim, Young‐Suk Lim Liver International.2025;[Epub] CrossRef
Comparison of the efficacy and action mechanism of Chinese patent medicines for liver fibrosis and cirrhosis Lingping Fu, Jin Xie, ZeXin Wang, Tao Jiang, Yi Zeng, Jing Yan, Rong Sun, Mengshuang Huang, Shengyi Du, Xiaobao Wang, Yuyang Liu, Kailai Xi, Ailin Chen, Xiao Ma, Jinhao Zeng, Thomas Efferth Phytomedicine.2025; 148: 157246. CrossRef
Longitudinal observation of chronic domestic cat hepadnavirus infection in cats with evidence of extrahepatic involvement Sabrina Wahyu Wardhani, Sitthichok Lacharoje, Tanit Kasantikul, Chutchai Piewbang, Somporn Techangamsuwan Journal of Feline Medicine and Surgery.2025;[Epub] CrossRef
Should Indications for Antiviral Therapy for Hepatitis B Be Broadened to Include Immune-Tolerant Patients, Inactive Carriers, or Patients in the “Gray Zone”? Yen-Chun Liu, Wen-Juei Jeng Current Hepatology Reports.2024; 23(1): 11. CrossRef
Stat3 activation-triggered transcriptional networks govern the early stage of HBV-induced hepatic inflammation Jinglin Tang, Jiaxuan Zhang, Gaoli Zhang, Wenhui Peng, Ning Ling, Yingzhi Zhou, Hongmei Xu, Hong Ren, Min Chen, Marthandan Mahalingam, Swati Jain mBio.2024;[Epub] CrossRef
Noninvasive Models to Assess Liver Inflammation and Fibrosis in Chronic HBV Infected Patients with Normal or Mildly Elevated Alanine Transaminase Levels: Which One Is Most Suitable? Shasha Ma, Lian Zhou, Shutao Lin, Mingna Li, Jing Luo, Lubiao Chen Diagnostics.2024; 14(5): 456. CrossRef
Lack of association between early on-treatment HBeAg seroclearance and development of hepatocellular carcinoma or decompensated cirrhosis Hyunjae Shin, Won-Mook Choi, Seung Up Kim, Yunmi Ko, Youngsu Park, Jeayeon Park, Moon Haeng Hur, Min Kyung Park, Yun Bin Lee, Yoon Jun Kim, Jung-Hwan Yoon, Jeong-Hoon Lee, Fabien Zoulim JHEP Reports.2024; 6(7): 101089. CrossRef
Inverse relationship between HBV DNA levels and liver histopathological changes in immune‐tolerant CHB patients Deliang Huang, Huiyi Lai, Zhibin Zhu, Hong Yu, Jinghan Peng, Yuanyuan Chen, Xuejiao Liao, Jun Chen Journal of Viral Hepatitis.2024; 31(7): 363. CrossRef
Editorial: High qHBsAg—is it a good or bad signal? Beom Kyung Kim Alimentary Pharmacology & Therapeutics.2024; 59(12): 1616. CrossRef
Lower HBV DNA level is associated with more severe liver fibrosis in HBeAg-positive chronic hepatitis B with normal alanine transaminase Jian Wang, Li Zhu, Zhiyi Zhang, Shaoqiu Zhang, Yifan Pan, Yuanyuan Li, Fei Cao, Chao Jiang, Tao Fan, Ye Xiong, Jiacheng Liu, Yuxin Chen, Shengxia Yin, Xin Tong, Chuanwu Zhu, Xingxiang Liu, Jie Li, Chao Wu, Rui Huang Virology Journal.2024;[Epub] CrossRef
Estimating the key outcomes and hepatocellular carcinoma risk in patients in immune‐tolerant phase of chronic hepatitis B virus infection: A systematic review and meta‐analysis Min Liu, Taixue Zhao, Jinyang Zhang, Bing Bu, Ruyi Zhang, Xueshan Xia, Jiawei Geng Reviews in Medical Virology.2024;[Epub] CrossRef
Significant liver histological change is common in HBeAg-positive chronic hepatitis B with normal ALT Menghui Duan, Huanming Xiao, Meijie Shi, Yubao Xie, Pengtao Zhao, Sheng Li, Xiaoling Chi, Xueen Liu, Hui Zhuang BMC Infectious Diseases.2024;[Epub] CrossRef
Preface Seung Up Kim Clinical and Molecular Hepatology.2024; 30(Suppl): S3. CrossRef
Vibration-controlled transient elastography for significant fibrosis in treatment-naïve chronic hepatitis B patients: A systematic review and meta-analysis Mi Na Kim, Jihyun An, Eun Hwa Kim, Hee Yeon Kim, Han Ah Lee, Jung Hwan Yu, Young-Joo Jin, Young Eun Chon, Seung Up Kim, Dae Won Jun, Ji Won Han, Miyoung Choi Clinical and Molecular Hepatology.2024; 30(Suppl): S106. CrossRef
HBeAg-positive CHB patients with indeterminate phase associated with a high risk of significant fibrosis Yuanyuan Li, Yijia Zhu, Dongmei Gao, Yifan Pan, Jian Wang, Shaoqiu Zhang, Xiaomin Yan, Li Zhu, Chuanwu Zhu, Xingxiang Liu, Zhaoping Zhang, Jie Li, Yuxin Chen, Rui Huang, Chao Wu Virology Journal.2024;[Epub] CrossRef
Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B? Joo Hyun Oh, Dong Hyun Sinn Clinical and Molecular Hepatology.2023; 29(2): 367. CrossRef
Letter regarding “Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase” Chia-Ming Chu, Yun-Fan Liaw Clinical and Molecular Hepatology.2023; 29(2): 510. CrossRef
The imitator of immune-tolerant chronic hepatitis B: A killer in disguise Moon Haeng Hur, Jeong-Hoon Lee Clinical and Molecular Hepatology.2023; 29(2): 363. CrossRef
Correspondence on Letter regarding “Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune tolerant phase” Jeong-Ju Yoo, Sang Gyune Kim Clinical and Molecular Hepatology.2023; 29(2): 513. CrossRef
Research Progress in Histological Features and Related Influencing Factors of Chronic Hepatitis B Patients with Persistent Normal ALT 宇行 刘 Advances in Clinical Medicine.2023; 13(05): 8702. CrossRef
Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study Chang Hun Lee, Gwang Hyeon Choi, Hwa Young Choi, Sojung Han, Eun Sun Jang, Young Eun Chon, Young Chang, Kyung-Ah Kim, Do Young Kim, Hyung Joon Yim, Hye-Lin Kim, Sook-Hyang Jeong, In Hee Kim Clinical and Molecular Hepatology.2023; 29(3): 779. CrossRef
Early portal hypertension in metabolic dysfunction-associated steatotic liver disease: a concise review Iván López-Méndez, Eva Juárez-Hernández, Juan Pablo Soriano-Márquez, Misael Uribe, Graciela Castro-Narro Expert Review of Gastroenterology & Hepatology.2025; 19(7): 755. CrossRef
Fibrosis-4plus score: a novel machine learning-based tool for screening high-risk varices in compensated cirrhosis (CHESS2004): an international multicenter study Bingtian Dong, Ruiling He, Shenghong Ju, Yuping Chen, Ivica Grgurevic, Jianzhong Ma, Ying Guo, Huizhen Fan, Qiang Yan, Chuan Liu, Huixiong Xu, Anita Madir, Kristian Podrug, Jia Wang, Linxue Qian, Zhengzi Geng, Shanghao Liu, Tao Ren, Guo Zhang, Kun Wang, M Clinical and Molecular Hepatology.2025; 31(3): 881. CrossRef
Correspondence on Letter regarding “Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune tolerant phase” Jeong-Ju Yoo, Sang Gyune Kim Clinical and Molecular Hepatology.2023; 29(2): 513. CrossRef
Han Ah Lee, Young Chang, Pil Soo Sung, Eileen L. Yoon, Hye Won Lee, Jeong-Ju Yoo, Young-Sun Lee, Jihyun An, Do Seon Song, Young Youn Cho, Seung Up Kim, Yoon Jun Kim
Clin Mol Hepatol 2022;28(3):425-472. Published online July 1, 2022
The global burden of chronic liver disease (CLD) is substantial. Due to the limited indication of and accessibility to antiviral therapy in viral hepatitis and lack of effective pharmacological treatment in nonalcoholic fatty liver disease, the beneficial effects of antidiabetics and non–antidiabetics in clinical practice have been continuously investigated in patients with CLD. In this narrative review, we focused on non-antidiabetic drugs, including ursodeoxycholic acid, silymarin, dimethyl4,4’-dimethoxy-5,6,5’,6’-dimethylenedixoybiphenyl-2,2’-dicarboxylate, L-ornithine L-aspartate, branched chain amino acids, statin, probiotics, vitamin E, and aspirin, and summarized their beneficial effects in CLD. Based on the antioxidant, anti-inflammatory properties, and regulatory functions in glucose or lipid metabolism, several non–antidiabetic drugs have shown beneficial effects in improving liver histology, aminotransferase level, and metabolic parameters and reducing risks of hepatocellular carcinoma and mortality, without significant safety concerns, in patients with CLD. Although the effect as the centerpiece management in patients with CLD is not robust, the use of these non-antidiabetic drugs might be potentially beneficial as an adjuvant or combined treatment strategy.
Citations
Citations to this article as recorded by
CYP4A14-PPARα axis serves as a therapeutic target for ursodeoxycholic acid in ameliorating high-fat diet-induced MASLD Bing Li, Pengjun Zhong, Xueling Zhang, Chengguo Li, Min Luan, Yanlin Chen, Lei Chen, Wu Li, Rihui Wu The Journal of Nutritional Biochemistry.2026; 147: 110138. CrossRef
An in vitro 3D spheroid model with liver steatosis and fibrosis on microwell arrays for drug efficacy evaluation Jiamin Chen, Ping Wang, Zhanpeng Li, Jieyi Wu, Fang Tang, Niao Yang, Bohong Cen, Cuiyin Xie, Yufan Yang, Ziyan Yang, Chuwen Zhang, Xiangcao Yao, Zhongyuan Xu Journal of Biotechnology.2025; 399: 153. CrossRef
KASL clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease 2025 Won Sohn, Young-Sun Lee, Soon Sun Kim, Jung Hee Kim, Young-Joo Jin, Gi-Ae Kim, Pil Soo Sung, Jeong-Ju Yoo, Young Chang, Eun Joo Lee, Hye Won Lee, Miyoung Choi, Su Jong Yu, Young Kul Jung, Byoung Kuk Jang Clinical and Molecular Hepatology.2025; 31(Suppl): S1. CrossRef
Pharmacotherapy in metabolic-dysfunction-associated steatotic liver disease: an updated review of the past, present and a promising future Sunetra Mondal, Amarta Shankar Chowdhury, Rajat Deb, Debmalya Sanyal Diabetology International.2025; 16(4): 678. CrossRef
Polymer-engineered delivery systems for Schisandra lignans: A review of advances in hepatic-targeted therapy Jia Zhou, Jiyuan Zhang, Jinzhuan Xu, Man Zhang, Yuanxing Huang, Zhengli Zhou, Hexinchen Tian, Jing Huang, Jianqing Peng, Runbin Sun, Yi Chen, Zipeng Gong International Journal of Biological Macromolecules.2025; 323: 147083. CrossRef
Letter on ‘Long‐Term Dynamic Changes of Alanine Aminotransferase Levels Are Associated With Liver‐Related Events in Nucleos(t)ide Analogue‐Treated Chronic Hepatitis B Patients in China’ Dong Hyun Kim, Hye Won Lee Alimentary Pharmacology & Therapeutics.2025; 62(9): 954. CrossRef
Modulation of Amomum tsao-ko on lipid metabolism and gut microbiota in high-fat diet-fed mice with NAFLD Zezhu Du, Lijun Yu, Jinya Dong, Linxian Shan, Jun He, Yan Shen, Yanmei Li, Xiuli Lu, Shengjie Duan, Jianyang Fu, Xiaocui Du, Yunfei Ge, Ruijuan Yang, Chongye Fang Journal of Agriculture and Food Research.2025; 24: 102379. CrossRef
Silymarin: Unveiling its pharmacological spectrum and therapeutic potential in liver diseases—A comprehensive narrative review Hafiza Madiha Jaffar, Fahad Al‐Asmari, Faima Atta Khan, Muhammad Abdul Rahim, Eliasse Zongo Food Science & Nutrition.2024; 12(5): 3097. CrossRef
The additive effect of herbal medicines on lifestyle modification in the treatment of non-alcoholic fatty liver disease: a systematic review and meta-analysis Myung-Ho Kim, Subin Ahn, Nayeon Hur, Seung-Yun Oh, Chang-Gue Son Frontiers in Pharmacology.2024;[Epub] CrossRef
Association between ursodeoxycholic acid use and COVID-19 in individuals with chronic liver disease: a nationwide case-control study in South Korea Sang Yi Moon, Minkook Son, Yeo Wool Kang, Myeongseok Koh, Jong Yoon Lee, Yang Hyun Baek Virology Journal.2024;[Epub] CrossRef
Evaluating the Role of Aspirin in Liver Disease: Efficacy, Safety, Potential Benefits and Risks Amani Elshaer, Blanca C. Lizaola-Mayo Life.2024; 14(12): 1701. CrossRef
Vitamin E and Pioglitazone: A Comprehensive Systematic Review of Their Efficacy in Non-alcoholic Fatty Liver Disease Iqra J Mazhar, Mohamed Yasir, Saba Sarfraz, Gandhala Shlaghya, Sri Harsha Narayana, Ujala Mushtaq, Basim Shaman Ameen, Chuhao Nie, Daniel Nechi, Sai Sri Penumetcha Cureus.2023;[Epub] CrossRef
ALT Is Not Associated With Achieving Subcirrhotic Liver Stiffness and HCC During Entecavir Therapy in HBV-Related Cirrhosis Mi Na Kim, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Se Young Jang, Won Young Tak, Young-Oh Kweon, Soo Young Park, Seung Up Kim Clinical Gastroenterology and Hepatology.2023; 21(9): 2278. CrossRef
Case 9: A 62-Year-Old Woman With Jaundice and General Weakness Hee Sun Cho, Ji Won Han, Ji Hoon Kim, Heechul Nam, Pil Soo Sung, Si Hyun Bae Journal of Korean Medical Science.2023;[Epub] CrossRef
Visión actual sobre el diagnóstico y los cuidados integrales en la encefalopatía hepática F. Higuera-de-la-Tijera, J.A. Velarde-Ruiz Velasco, R.H. Raña-Garibay, G.E. Castro-Narro, J.M. Abdo-Francis, R. Moreno-Alcántar, J.L. Pérez-Hernández, A. Torre, R. Contreras-Omaña, A. Cano-Contreras, M. Castillo-Barradas, J. Pérez-Escobar, J.M. Aldana-Led Revista de Gastroenterología de México.2023; 88(2): 155. CrossRef
Current vision on diagnosis and comprehensive care in hepatic encephalopathy F. Higuera-de-la-Tijera, J.A. Velarde-Ruiz Velasco, R.H. Raña-Garibay, G.E. Castro-Narro, J.M. Abdo-Francis, R. Moreno-Alcántar, J.L. Pérez-Hernández, A. Torre, R. Contreras-Omaña, A. Cano-Contreras, M. Castillo-Barradas, J. Pérez-Escobar, J.M. Aldana-Led Revista de Gastroenterología de México (English Edition).2023; 88(2): 155. CrossRef
Multiple Hepatic Artery Pseudoaneurysms With Eosinophilia Mun Young Cho, Pil Soo Sung, Sung Hak Lee Gastroenterology.2023; 165(4): 843. CrossRef
Inhibition of Dickkopf-1 enhances the anti-tumor efficacy of sorafenib via inhibition of the PI3K/Akt and Wnt/β-catenin pathways in hepatocellular carcinoma Sang Hyun Seo, Kyung Joo Cho, Hye Jung Park, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Jae Hee Cheon, Jong In Yook, Man-Deuk Kim, Dong Jin Joo, Seung Up Kim Cell Communication and Signaling.2023;[Epub] CrossRef
Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach Michael H. Le, Yee Hui Yeo, Biyao Zou, Scott Barnet, Linda Henry, Ramsey Cheung, Mindie H. Nguyen Clinical and Molecular Hepatology.2022; 28(4): 841. CrossRef
CSAD Ameliorates Lipid Accumulation in High-Fat Diet-Fed Mice Rongrong Tan, Jiayang Li, Lu Liu, Qian Wu, Lei Fan, Ningning Ma, Chuwei Yu, Henglei Lu, Xuemei Zhang, Jing Chen, Likun Gong, Jin Ren International Journal of Molecular Sciences.2022; 23(24): 15931. CrossRef
Genotype–Phenotype Association in ABCC2 Exon 18 Missense Mutation Leading to Dubin–Johnson Syndrome: A Case Report Ji-Hoon Kim, Min-Woo Kang, Sangmi Kim, Ji Won Han, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon, Pil Soo Sung International Journal of Molecular Sciences.2022; 23(24): 16168. CrossRef
Seong Hee Kang, Hye Won Lee, Jeong-Ju Yoo, Yuri Cho, Seung Up Kim, Tae Hee Lee, Byoung Kuk Jang, Sang Gyune Kim, Sang Bong Ahn, Haeryoung Kim, Dae Won Jun, Joon-Il Choi, Do Seon Song, Won Kim, Soung Won Jeong, Moon Young Kim, Hong Koh, Sujin Jeong, Jin-Woo Lee, Yong Kyun Cho, on behalf of The Korean Association for the Study of the Liver (KASL)
Clin Mol Hepatol 2021;27(3):363-401. Published online June 22, 2021
Effects of Intermittent Calorie Restriction in Nondiabetic Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease Han Ah Lee, Hyeyoung Moon, Yuri Kim, Jeong Kyong Lee, Hye Ah Lee, Hwi Young Kim Clinical Gastroenterology and Hepatology.2025; 23(1): 114. CrossRef
Serum Ferritin Levels and Liver‐Related Events in Individuals With Steatotic Liver Disease: A Longitudinal Cohort Study Byeong Geun Song, Myung Ji Goh, Wonseok Kang, Geum‐Youn Gwak, Yong‐Han Paik, Moon Seok Choi, Joon Hyeok Lee, Dong Hyun Sinn Alimentary Pharmacology & Therapeutics.2025; 61(3): 491. CrossRef
Differential Exercise Requirements for Nonalcoholic Fatty Liver Disease Resolution Across Age Groups: A Longitudinal Study of Korean Military Officers Jaejun Lee, Dong Yeup Lee, Jae Hyeop Jung, Eunkyoung Bae, Jeong A. Yu, Hyun Yang Journal of Physical Activity and Health.2025; 22(3): 323. CrossRef
The Role of microRNA-22 in Metabolism Simone Tomasini, Paolo Vigo, Francesco Margiotta, Ulrik Søberg Scheele, Riccardo Panella, Sakari Kauppinen International Journal of Molecular Sciences.2025; 26(2): 782. CrossRef
Performance of Noninvasive Indices for Discrimination of Metabolic Dysfunction-Associated Steatotic Liver Disease in Young Adults Jaejun Lee, Chang In Han, Dong Yeup Lee, Pil Soo Sung, Si Hyun Bae, Hyun Yang Gut and Liver.2025; 19(1): 116. CrossRef
Evidence summary of lifestyle interventions in adults with metabolic dysfunction-associated steatotic liver disease Mei-jing Chen, Ying Chen, Jin-qing Lin, Rong Hu, Dun Liu, Jing-yi Chen, Ka Li, Xiao-ying Jiang Frontiers in Nutrition.2025;[Epub] CrossRef
Diagnostic Accuracy of Non-Invasive Diagnostic Tests for Nonalcoholic Fatty Liver Disease: A Systematic Review and Network Meta-Analysis Yuxin Sun, Die Hu, Mingkun Yu, Shi-Bing Liang, Youyou Zheng, Xin Wang, Guangdong Tong Clinical Epidemiology.2025; Volume 17: 53. CrossRef
Cardiovascular Risk From Metabolic Dysfunction-Associated Steatotic Liver Disease, Cardiometabolic Risk Factor Count, and Their Longitudinal Changes: A Nationwide Cohort Study Hyeok-Hee Lee, Han Ah Lee, Eun-Jin Kim, Hwi Young Kim, Hyeon Chang Kim, Sang Hoon Ahn, Hokyou Lee, Seung Up Kim American Journal of Gastroenterology.2025; 120(10): 2321. CrossRef
Comparing non-alcoholic fatty liver disease indices in predicting the prevalence and incidence of metabolic syndrome in middle-aged adults Byung Sik Kim, Hyun-Jin Kim, Seong Won Jeon, Kyung Hwan Kim, Dong Wook Kim, Jeong-Hun Shin Heliyon.2025; 11(7): e43073. CrossRef
Impact of cardiometabolic risk factors on hepatic fibrosis and clinical outcomes in MASLD: A population-based multi-cohort study Huiyul Park, Terry Cheuk-Fung Yip, Eileen L. Yoon, Grace Lai-Hung Wong, Hye Sun Lee, Vincent Wai-Sun Wong, Jimmy Che-To Lai, Dae Won Jun JHEP Reports.2025; 7(6): 101388. CrossRef
KASL clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease 2025 Won Sohn, Young-Sun Lee, Soon Sun Kim, Jung Hee Kim, Young-Joo Jin, Gi-Ae Kim, Pil Soo Sung, Jeong-Ju Yoo, Young Chang, Eun Joo Lee, Hye Won Lee, Miyoung Choi, Su Jong Yu, Young Kul Jung, Byoung Kuk Jang Clinical and Molecular Hepatology.2025; 31(Suppl): S1. CrossRef
The association between modified cardiometabolic index with non-alcoholic fatty liver disease and liver fibrosis: a cross-sectional study Yanjun Guo, Wei Su, Lulong Tao, Guoxin Zhang, Kun Wang BMC Gastroenterology.2025;[Epub] CrossRef
Sex differences in the mediation of the MASLD - Depression association by fat distribution in U.S. adults Changhuai He, Liuxin Zhou, Tianming Gao, Runmin Cao, Chuanqi Cai, Guoqing Jiang Acta Psychologica.2025; 256: 105041. CrossRef
Association Between Perfluoroalkyl Substance (PFAS) Exposure and Nonalcoholic Fatty Liver Disease in Korean Adults: Results From the KoNEHS 2018–2020: A Cross‐Sectional Study Jisuk Yun, Young‐Sun Min American Journal of Industrial Medicine.2025; 68(7): 588. CrossRef
Valorization of grape pomace by microbial fermentation: Composition, biological activities and potential applications for the food industry Kavindya Samarakoon, H.P. Vasantha Rupasinghe Journal of Food Composition and Analysis.2025; 144: 107656. CrossRef
Managing Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in Primary Care Settings: A Review Vignesh Rajan, Ambarish Das, J. Venkatachalam, K. K. Lohani, Chandrakant Lahariya Preventive Medicine: Research & Reviews.2025; 2(4): 183. CrossRef
Cost-effectiveness analysis of MASLD screening using FIB-4 based two-step algorithm in the medical check-up Mimi Kim, Huiyul Park, Eileen L. Yoon, Ramsey Cheung, Donghee Kim, Hye-Lin Kim, Dae Won Jun Scientific Reports.2025;[Epub] CrossRef
Are mesenchymal stem/stromal cells a novel avenue for the treatment of non-alcoholic fatty liver disease? Milton Artur Ruiz, Roberto Luiz R Kaiser Junior, Gabriel Piron-Ruiz, Luiz Gustavo de Quadros World Journal of Stem Cells.2025;[Epub] CrossRef
The ameliorative effect of C-Kit+ hepatic endothelial cells with Mertk deficiency on nonalcoholic steatohepatitis Seng-Wang Fu, Yu-Xuan Gao, Hui-Yi Li, Jun-Cheng Wu, Zheng-Hong Li, Ming-Yi Xu Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.2025; 1871(7): 167964. CrossRef
Role of amino acids in the regulation of hepatic gluconeogenesis and lipogenesis in metabolic dysfunctionassociated steatotic liver disease Eiji Kakazu, Masaaki Mino, Tatsuya Kanto Clinical and Molecular Hepatology.2025; 31(3): 771. CrossRef
Chemical profile of Ficus lyrata bark extract and its therapeutic effect on non-alcoholic fatty liver disease via regulating oxidative stress, inflammation and hepatic lipogenesis Amria Mamdouh Mousa, Rehab Fikry Taher, Nermin Mohamed El-Sammad, Esraa Aly Balabel, Elham Mohamed Youssef, Ahmed Hassan Afifi, Sahar Samir Abdel-Rahman, Nayera Anwar, Sherien Kamal Hassan BMC Complementary Medicine and Therapies.2025;[Epub] CrossRef
Metabolic Dysfunction–Associated Steatotic Liver Disease, Alcohol Consumption, and the Risk of Atrial Fibrillation: A Nationwide Population‐Based Study Minkwan Kim, Minkook Son, Sang Yi Moon, Yang Hyun Baek Journal of the American Heart Association.2025;[Epub] CrossRef
Comparison of sarcopenia screening indices using serum creatinine and cystatin C in metabolic dysfunction-associated steatotic liver disease Inyoung Hwang, Shi-Ra Lee, Yun Kim, Sang Won Lee Frontiers in Medicine.2025;[Epub] CrossRef
Exercise training improves metabolic and circulatory function in COPD patients with NAFLD: evidence from clinical and molecular profiling Yi-cai Qian, Xiaoxiang Liu, Panpan Liu, ShuYing Jia, Yi Ding, Cuiling Zhu, Jing He Frontiers in Medicine.2025;[Epub] CrossRef
Comparison of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Patients with Steatotic Liver Disease Yunmi Ko, Moon Haeng Hur, Youngsu Park, Jeayeon Park, Hyunjae Shin, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim Gut and Liver.2025; 19(5): 758. CrossRef
Diet and Lifestyle Interventions in Metabolic Dysfunction-Associated Fatty Liver Disease: A Comprehensive Review Muhammad Y. Sheikh, Muhammad F. Younus, Annie Shergill, Muhammad N. Hasan International Journal of Molecular Sciences.2025; 26(19): 9625. CrossRef
Association of Rapid Early Weight Loss with One-Year Hepatic Steatosis Improvement After Sleeve Gastrectomy: A Retrospective Cohort Study Min Kyoung Jang, Si Yeol Yoon, Jin A. An, Ji Soo Kim, Min-Seon Kim, Jung Ah Lee, Chang Seok Ko, Se Hee Min Journal of Clinical Medicine.2025; 14(20): 7284. CrossRef
Metabolic dysfunction-associated steatotic liver disease in Egypt: Epidemiology, risk factors and management challenges Walaa Abdelhamed, Mona Amin, Imam Waked, Mohamed El-Kassas World Journal of Gastroenterology.2025;[Epub] CrossRef
Fibrotic Burden in Patients With Hepatitis B Virus–Related Cirrhosis Is Independently Associated With Poorer Kidney Outcomes Chan-Young Jung, Hui-Yun Jung, Hyung Woo Kim, Geun Woo Ryu, Jung Il Lee, Sang Hoon Ahn, Seung Up Kim, Beom Seok Kim The Journal of Infectious Diseases.2024; 229(1): 108. CrossRef
A Comparison of the Prognostic Value of Liver Fibrosis Scores in Acute Myocardial Infarction Patients With and Without Type 2 Diabetes Hao-ming He, Shu-wen Zheng, Yi-nong Chen, Long-yang Zhu, Zhe Wang, Si-qi Jiao, Fu-rong Yang, Yi-hong Sun Angiology.2024; 75(3): 219. CrossRef
Navigating nonalcoholic fatty liver disease (NAFLD): Exploring the roles of estrogens, pharmacological and medical interventions, and life style Qianying Zuo, Nicole Hwajin Park, Jenna Kathryn Lee, Ashlie Santaliz-Casiano, Zeynep Madak-Erdogan Steroids.2024; 203: 109330. CrossRef
Association between plant-based diets and risk of metabolic dysfunction–associated steatotic liver disease in Korean adults: A prospective cohort study Bayarmaa Nasan Ulzii, Kyungjoon Lim, Sangah Shin Nutrition.2024; 128: 112579. CrossRef
Extrahepatic malignancies in metabolic dysfunction‐associated fatty liver disease: A nationwide cohort study Min Kyung Park, Moon Haeng Hur, Hye‐Sung Moon, Hyunjae Shin, Sung Won Chung, Sungho Won, Yun Bin Lee, Eun Ju Cho, Jeong‐Hoon Lee, Su Jong Yu, Jung‐Hwan Yoon, Yoon Jun Kim Liver International.2024; 44(3): 799. CrossRef
Performance Evaluation of a Novel Non-Invasive Test for the Detection of Advanced Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease Anna Stefanska, Katarzyna Bergmann, Szymon Suwała, Aneta Mankowska-Cyl, Marek Kozinski, Roman Junik, Magdalena Krintus, Mauro Panteghini Metabolites.2024; 14(1): 52. CrossRef
Very low-carbohydrate diet with higher protein ratio improves lipid metabolism and inflammation in rats with diet-induced nonalcoholic fatty liver disease I-Ting Wu, Wan-Ju Yeh, Wen-Chih Huang, Hsin-Yi Yang The Journal of Nutritional Biochemistry.2024; 126: 109583. CrossRef
Quality Evaluation of Metabolic-Associated Fatty Liver Disease
Guidelines and Expert Consensus Meijing Chen, Ying Chen, Dun Liu, Ka Li, Rong Hu, Jingyi Chen, Xiaoying Jiang, Jinqing Lin Hormone and Metabolic Research.2024; 56(07): 509. CrossRef
Integrated traditional Chinese and Western medicine in the prevention and treatment of non-alcoholic fatty liver disease: future directions and strategies Xin Ding, Xu He, Bulang Tang, Tian Lan Chinese Medicine.2024;[Epub] CrossRef
Outcomes of Various Classes of Oral Antidiabetic Drugs on Nonalcoholic Fatty Liver Disease Heejoon Jang, Yeonjin Kim, Dong Hyeon Lee, Sae Kyung Joo, Bo Kyung Koo, Soo Lim, Woojoo Lee, Won Kim JAMA Internal Medicine.2024; 184(4): 375. CrossRef
Mobile App–Based Lifestyle Coaching Intervention for Patients With Nonalcoholic Fatty Liver Disease: Randomized Controlled Trial Oh Young Kwon, Mi Kyung Lee, Hye Won Lee, Hyerang Kim, Jae Seung Lee, Yeonsoo Jang Journal of Medical Internet Research.2024; 26: e49839. CrossRef
Non-invasive diagnosis of non-alcoholic fatty liver disease: Current status and future perspective Jia-Lan Wang, Su-Wen Jiang, Ai-Rong Hu, Ai-Wu Zhou, Ting Hu, Hong-Shan Li, Ying Fan, Ken Lin Heliyon.2024; 10(5): e27325. CrossRef
Assessment of Hepatic Steatosis Using Ultrasound-Based Techniques: Focus on Fat Quantification Woo Sun Rou Clinical Ultrasound.2024; 9(1): 1. CrossRef
Hepatic Steatosis but Not Fibrosis Is Independently Associated with Poor Outcomes in Patients with Inflammatory Bowel Disease Hye Kyung Hyun, Hye Won Lee, Jihye Park, Soo Jung Park, Jae Jun Park, Tae Il Kim, Jae Seung Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim, Jae Hee Cheon Gut and Liver.2024; 18(2): 294. CrossRef
The associations between fibrosis changes and liver‐related events in patients with metabolic dysfunction‐associated steatotic liver disease Hye Won Lee, Kun Hee Kim, Sang Hoon Ahn, Han Chu Lee, Jonggi Choi Liver International.2024; 44(6): 1448. CrossRef
Independent and joint association of physical activity and adequate weekday sleep duration with metabolic dysfunction-associated steatotic liver disease Yaxin Li, Yitian Guo, Shiyun Tan Clinics and Research in Hepatology and Gastroenterology.2024; 48(4): 102320. CrossRef
Risk of Hepatocellular Carcinoma by Steatotic Liver Disease and Its Newly Proposed Subclassification Byeong Geun Song, Aryoung Kim, Myung Ji Goh, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Dong Hyun Sinn Liver Cancer.2024; 13(5): 561. CrossRef
Sleep factors were associated with a higher risk of MAFLD and significant fibrosis Yaxin Li, Shiyun Tan Sleep and Breathing.2024; 28(3): 1381. CrossRef
Puerarin Induces Macrophage M2 Polarization to Exert Antinonalcoholic Steatohepatitis Pharmacological Activity via the Activation of Autophagy Xiaoxue Fang, Xintian Lan, Ming Zhu, Min He, Mengmeng Sun, Yiming Cao, Difu Zhu, Dean Guo, Haoming Luo Journal of Agricultural and Food Chemistry.2024; 72(13): 7187. CrossRef
Steatotic liver disease and its newly proposed sub-classifications correlate with progression of the coronary artery calcium score Aryoung Kim, Danbee Kang, Sung Chul Choi, Juhee Cho, Dong Hyun Sinn, Geum-Youn Gwak, Ashraf Elbahrawy PLOS ONE.2024; 19(3): e0301126. CrossRef
Comparison between Nivolumab and Regorafenib as Second-line Systemic Therapies after Sorafenib Failure in Patients with Hepatocellular Carcinoma Hong Jun Lee, Jae Seung Lee, Hyesung So, Ja Kyung Yoon, Jin-Young Choi, Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Do Young Kim Yonsei Medical Journal.2024; 65(7): 371. CrossRef
Diagnostic performances of Fibrosis‐4 index and nonalcoholic fatty liver disease fibrosis score in metabolic dysfunction‐associated steatotic liver disease in Asian primary care clinics Huiyul Park, Mimi Kim, Hye‐Lin Kim, Seon Cho, Eileen L. Yoon, Dae Won Jun Hepatology Research.2024; 54(11): 1027. CrossRef
Harnessing Metabolic Indices as a Predictive Tool for Cardiovascular Disease in a Korean Population without Known Major Cardiovascular Event Hyun-Jin Kim, Byung Sik Kim, Yonggu Lee, Sang Bong Ahn, Dong Wook Kim, Jeong-Hun Shin Diabetes & Metabolism Journal.2024; 48(3): 449. CrossRef
An Exploration of the Treatment of Non-Alcoholic Fatty Liver Disease Based on Dietary Factors Wanzhou Yang, Y.-T. Yu, P.P. Piccaluga, S. Xie BIO Web of Conferences.2024; 111: 03024. CrossRef
Assessing the Utility of Acoustic Radiation Force Impulse in the Evaluation of Non-Alcoholic Fatty Liver Disease with Severe Obesity or Steatosis Yeo Wool Kang, Yang Hyun Baek, Jong Hoon Lee, Young Hoon Roh, Hee Jin Kwon, Sang Yi Moon, Min Kook Son, Jin Sook Jeong Diagnostics.2024; 14(11): 1083. CrossRef
Diagnostic performance of non-invasive tests in patients with MetALD in a health check-up cohort Joo Hyun Oh, Sang Bong Ahn, Seon Cho, Eun-Hee Nah, Eileen L. Yoon, Dae Won Jun Journal of Hepatology.2024; 81(5): 772. CrossRef
A Novel Antioxidant, Hydrogen-Rich Coral Calcium Alters Gut Microbiome and Bile Acid Synthesis to Improve Methionine-and-Choline-Deficient Diet-Induced Non-Alcoholic Fatty Liver Disease Hung-Tsung Wu, Chin-Shiang Tsai, Ting-Hsing Chao, Horng-Yih Ou, Liang-Miin Tsai Antioxidants.2024; 13(6): 746. CrossRef
Evaluation of pancreatic iodine uptake and related influential factors in multiphase dual-energy CT Chen Pan, Tao Yu, Heng Zhao, Jiani He, Xiaomei Lu, Haiyan Tang, Yang Hong, Chao Shang, Qijun Wu, Aoran Yang, Chunli Li, Minghui Zhou, Yu Shi European Radiology.2024; 34(12): 7609. CrossRef
Comparative effects of lifelong moderate-intensity continuous training and high-intensity interval training on blood lipid levels and mental well-being in naturally ageing mice Ling Yang, Wentao Lin, Xu Yan, Zhishang Zhang Experimental Gerontology.2024; 194: 112519. CrossRef
The Effect of Mobile Lifestyle Intervention Combined with High-Protein Meal Replacement on Liver Function in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Pilot Randomized Controlled Trial Eunbyul Cho, Sunwoo Kim, Soonkyu Kim, Ju Young Kim, Hwa Jung Kim, Yumi Go, Yu Jung Lee, Haesol Lee, Siye Gil, Sung Kwon Yoon, Keonho Chu Nutrients.2024; 16(14): 2254. CrossRef
Epidemiology, pathophysiology and clinical aspects of Hepatocellular Carcinoma in MAFLD patients Maria Eva Argenziano, Mi Na Kim, Michele Montori, Alessandro Di Bucchianico, Daniele Balducci, Sang Hoon Ahn, Gianluca Svegliati Baroni Hepatology International.2024; 18(S2): 922. CrossRef
A New Korean Nomenclature for Steatotic Liver Disease
The Korean Journal of Gastroenterology.2024; 84(1): 1. CrossRef
Barriers to care linkage and educational impact on unnecessary MASLD referrals Jun-Hyuk Lee, Eileen Laurel Yoon, Ju Hyun Oh, Kyunam Kim, Sang Bong Ahn, Dae Won Jun Frontiers in Medicine.2024;[Epub] CrossRef
Immune system dysregulation in the pathogenesis of non-alcoholic steatohepatitis: unveiling the critical role of T and B lymphocytes Merve Cebi, Yusuf Yilmaz Frontiers in Immunology.2024;[Epub] CrossRef
A New Korean Nomenclature for Steatotic Liver Disease
The Korean Journal of Medicine.2024; 99(4): 189. CrossRef
Agile 3+ and Agile 4 scores predict chronic kidney disease development in metabolic dysfunction‐associated steatotic liver disease Chan‐Young Jung, Jung Il Lee, Sang Hoon Ahn, Seung Up Kim, Beom Seok Kim Alimentary Pharmacology & Therapeutics.2024; 60(8): 1051. CrossRef
A New Korean Nomenclature for Steatotic Liver Disease
A new Korean nomenclature for steatotic liver disease
Clinical and Molecular Hepatology.2024; 30(Suppl): S214. CrossRef
Metabolic dysfunction‐associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: A nationwide cohort study Yewan Park, Jooyi Jung, Seungbong Han, Gi‐Ae Kim Alimentary Pharmacology & Therapeutics.2024; 60(11-12): 1599. CrossRef
Comparative associations of MASLD and MAFLD with the presence and severity of coronary artery calcification Min Kyu Kang, Jeong Eun Song, Rohit Loomba, Soo Young Park, Won Young Tak, Young Oh Kweon, Yu Rim Lee, Jung Gil Park Scientific Reports.2024;[Epub] CrossRef
A narrative review of lifestyle management guidelines for metabolic dysfunction–associated steatotic liver disease Dana Ivancovsky Wajcman, Christopher J. Byrne, John F. Dillon, Paul N. Brennan, Marcela Villota-Rivas, Zobair M. Younossi, Alina M. Allen, Javier Crespo, Lynn H. Gerber, Jeffrey V. Lazarus Hepatology.2024;[Epub] CrossRef
Visceral Obesity and Its Association with Severe Coronary Artery Calcification in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease Min Kyu Kang, Jeung Eun Song, Young Oh Kweon, Won Young Tak, Soo Young Park, Yu Rim Lee, Jung Gil Park Diagnostics.2024; 14(20): 2305. CrossRef
Pathogenesis and management of metabolic dysfunction-associated
steatohepatitis-related hepatocellular carcinoma: a narrative
review Han Ah Lee The Ewha Medical Journal.2024;[Epub] CrossRef
Evaluation of hepatoprotective and nephroprotective activities of Castanopsis costata extract in rats Maulana Alkandahri, Asman Sadino, Ermi Abriyani, Faizal Hermanto, Zulpakor Oktoba, Muhammad Sayoeti, Putu Sangging, Diah Wardani, Nahrul Hasan, Suci Sari, Nurul Safitri, Windi Ikhtianingsih, Safitri Safitri Biomedical Reports.2024;[Epub] CrossRef
Cross-talk between gut microbiota and liver steatosis: Complications and therapeutic target Yuan Yao, Yunfeng Shen Open Life Sciences.2023;[Epub] CrossRef
Association of Physical Activity With Risk of Liver Fibrosis, Sarcopenia, and Cardiovascular Disease in Nonalcoholic Fatty Liver Disease Ho Soo Chun, Minjong Lee, Hye Ah Lee, Seo Yeong Oh, Hyo Jeong Baek, Jae Won Moon, Yeon Jeong Kim, Jinha Lee, Hyoeun Kim, Hwi Young Kim, Kwon Yoo, Tae Hun Kim, Seung Up Kim Clinical Gastroenterology and Hepatology.2023; 21(2): 358. CrossRef
Nonalcoholic Fatty Liver Disease Without Metabolic-associated Fatty Liver Disease and the Risk of Metabolic Syndrome Dong Hyun Sinn, Danbee Kang, Sung Chul Choi, Yun Soo Hong, Di Zhao, Eliseo Guallar, Yewan Park, Juhee Cho, Geum-Youn Gwak Clinical Gastroenterology and Hepatology.2023; 21(7): 1873. CrossRef
The association of non‐alcoholic fatty liver disease between parents and adolescent children Yewan Park, Dong Hyun Sinn, Kyunga Kim, Geum‐Youn Gwak Alimentary Pharmacology & Therapeutics.2023; 57(2): 245. CrossRef
Statin use is associated with better post‐operative prognosis among patients with hepatitis B virus‐related hepatocellular carcinoma Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin‐Ha Yoon, Beom Kyung Kim European Journal of Clinical Investigation.2023;[Epub] CrossRef
Reply Dong Hyun Sinn, Danbee Kang, Eliseo Guallar, Juhee Cho, Geum-Youn Gwak Clinical Gastroenterology and Hepatology.2023; 21(9): 2435. CrossRef
Positive association between nonalcoholic fatty liver disease and growth hormone deficiency in patients with nonfunctioning pituitary adenoma Yoon-a Hwang, Hye Won Lee, Sang Hoon Ahn, Eun Jig Lee, Cheol Ryong Ku, Seung Up Kim Frontiers in Endocrinology.2023;[Epub] CrossRef
Ideal cardiovascular health metrics and the risk of nonalcoholic fatty liver disease in Korean adults Sun Young Shim, Sun Jae Jung, Seung Up Kim, Hyeon Chang Kim Clinical Hypertension.2023;[Epub] CrossRef
Correspondence on Editorial regarding “Impact of nationwide hepatocellular carcinoma surveillance on the prognosis in patients with chronic liver disease” Won Sohn, Yong-Han Paik Clinical and Molecular Hepatology.2023; 29(1): 182. CrossRef
Correspondence on Editorial regarding “Screening and prediction of nonalcoholic fatty liver disease using a peripheral insulin resistance index: Potential benefits and limitations” Jun-Hyuk Lee, Kyongmin Park, Hye Sun Lee, Hoon-Ki Park, Jee Hye Han, Sang Bong Ahn Clinical and Molecular Hepatology.2023; 29(1): 185. CrossRef
Correspondence on Letter regarding “Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways” Seung Min Lee, Dae Won Jun Clinical and Molecular Hepatology.2023; 29(1): 171. CrossRef
Correspondence on Letter regarding “The usefulness of metabolic score for insulin resistance for the prediction of incident non-alcoholic fatty liver disease in Korean adults” Jun-Hyuk Lee, Kyongmin Park, Hye Sun Lee, Hoon-Ki Park, Jee Hye Han, Sang Bong Ahn Clinical and Molecular Hepatology.2023; 29(1): 179. CrossRef
Recurrence of hepatocellular carcinoma in noncirrhotic patients with nonalcoholic fatty liver disease versus hepatitis B infection Jungnam Lee, Jong-In Chang, Young-Joo Jin, Jeong-Hoon Lee, Ju Yeon Kim, Dong Hyun Sinn, Soon Sun Kim, Hyun Woong Lee, Sun Hong Yoo, Jung Hwan Yu, Jin-Woo Lee European Journal of Gastroenterology & Hepatology.2023; 35(4): 431. CrossRef
Comparison of Guidelines for the Screening, Diagnosis, and Noninvasive Assessment of Nonalcoholic Fatty Liver Disease Kenneth W. Chow, Pragyat Futela, Aryan Saharan, Sammy Saab Journal of Clinical and Experimental Hepatology.2023; 13(5): 783. CrossRef
Clinical Implications of Cardiac Symptoms and Electrocardiographic Abnormalities for Advanced Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease Min-Kyu Kang, Min-Cheol Kim Medicina.2023; 59(2): 375. CrossRef
The independent effect of exercise on biopsy-proven non-alcoholic fatty liver disease: A systematic review George Chen, Bubu Banini, Albert Do, Joseph K. Lim Clinical and Molecular Hepatology.2023; 29(Suppl): S319. CrossRef
Preventive strategy for nonalcoholic fatty liver disease-related hepatocellular carcinoma Yuri Cho, Bo Hyun Kim, Joong-Won Park Clinical and Molecular Hepatology.2023; 29(Suppl): S220. CrossRef
Global incidence and prevalence of nonalcoholic fatty liver disease Margaret LP Teng, Cheng Han Ng, Daniel Q. Huang, Kai En Chan, Darren JH Tan, Wen Hui Lim, Ju Dong Yang, Eunice Tan, Mark D. Muthiah Clinical and Molecular Hepatology.2023; 29(Suppl): S32. CrossRef
Non-alcoholic fatty liver disease: the pathologist’s perspective Wei-Qiang Leow, Anthony Wing-Hung Chan, Paulo Giovanni L. Mendoza, Regina Lo, Kihan Yap, Haeryoung Kim Clinical and Molecular Hepatology.2023; 29(Suppl): S302. CrossRef
Preventive effect of empagliflozin and ezetimibe on hepatic steatosis in adults and murine models Dong Yun Kim, Kyu Sik Chung, Jun Yong Park, Heon Yung Gee Biomedicine & Pharmacotherapy.2023; 161: 114445. CrossRef
Effects of additive interactions among obesity, visceral adiposity, and sarcopenia on nonalcoholic fatty liver disease Goh Eun Chung, Sohee Oh, Dong-Won Ahn, Su Hwan Kim, Yong Jin Jung, Ji Won Kim, Byeong Gwan Kim, Kook Lae Lee, Ji Bong Jeong Scientific Reports.2023;[Epub] CrossRef
Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future Tina Reinson, Ryan M. Buchanan, Christopher D. Byrne Clinical and Molecular Hepatology.2023; 29(Suppl): S157. CrossRef
Baseline Tyrosine Level Is Associated with Dynamic Changes in FAST Score in NAFLD Patients under Lifestyle Modification Hwi Young Kim, Da Jung Kim, Hye Ah Lee, Joo-Youn Cho, Won Kim Metabolites.2023; 13(3): 444. CrossRef
Nonalcoholic fatty liver disease and non-liver comorbidities Richie Manikat, Mindie H. Nguyen Clinical and Molecular Hepatology.2023; 29(Suppl): s86. CrossRef
Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease Peter Konyn, Aijaz Ahmed, Donghee Kim Clinical and Molecular Hepatology.2023; 29(Suppl): S43. CrossRef
Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials Jihyun An, Joo Hyun Sohn Clinical and Molecular Hepatology.2023; 29(Suppl): S268. CrossRef
Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments Sang Bong Ahn Clinical and Molecular Hepatology.2023; 29(Suppl): S150. CrossRef
Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future Asako Nogami, Masato Yoneda, Michihiro Iwaki, Takashi Kobayashi, Yasushi Honda, Yuji Ogawa, Kento Imajo, Satoru Saito, Atsushi Nakajima Clinical and Molecular Hepatology.2023; 29(Suppl): S123. CrossRef
Comparison between obese and non-obese nonalcoholic fatty liver disease Wah-Kheong Chan Clinical and Molecular Hepatology.2023; 29(Suppl): S58. CrossRef
Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future Jung Hwan Yu, Han Ah Lee, Seung Up Kim Clinical and Molecular Hepatology.2023; 29(Suppl): S136. CrossRef
Eating, diet, and nutrition for the treatment of non-alcoholic fatty liver disease Georg Semmler, Christian Datz, Michael Trauner Clinical and Molecular Hepatology.2023; 29(Suppl): S244. CrossRef
Non-alcoholic fatty liver disease: Definition and subtypes Seul Ki Han, Soon Koo Baik, Moon Young Kim Clinical and Molecular Hepatology.2023; 29(Suppl): S5. CrossRef
The effects of moderate alcohol consumption on non-alcoholic fatty liver disease Hyunwoo Oh, Won Sohn, Yong Kyun Cho Clinical and Molecular Hepatology.2023; 29(Suppl): S261. CrossRef
Surveillance of the progression and assessment of treatment endpoints for nonalcoholic steatohepatitis Yi-wen Shi, Jian-Gao Fan Clinical and Molecular Hepatology.2023; 29(Suppl): S228. CrossRef
Bariatric surgery for non-alcoholic fatty liver disease: Indications and post-operative management Anja Geerts, Sander Lefere Clinical and Molecular Hepatology.2023; 29(Suppl): S276. CrossRef
Liver transplantation for non-alcoholic fatty liver disease: indications and post-transplant management Sara Battistella, Francesca D’Arcangelo, Marco Grasso, Alberto Zanetto, Martina Gambato, Giacomo Germani, Marco Senzolo, Francesco Paolo Russo, Patrizia Burra Clinical and Molecular Hepatology.2023; 29(Suppl): S286. CrossRef
CT-based Hounsfield unit values reflect the degree of steatohepatitis in patients with low-grade fatty liver disease Ha Neul Kim, Hong Jae Jeon, Hei Gwon Choi, In Sun Kwon, Woo Sun Rou, Jeong Eun Lee, Tae Hee Lee, Seok Hyun Kim, Byung Seok Lee, Kyung Sook Shin, Hyun Jung Lee, Hyuk Soo Eun BMC Gastroenterology.2023;[Epub] CrossRef
How many times should we repeat measurements of the ultrasound-guided attenuation parameter for evaluating hepatic steatosis? Duck Min Seo, Sang Min Lee, Ji Won Park, Min-Jeong Kim, Hong Il Ha, Sun-Young Park, Kwanseop Lee Ultrasonography.2023; 42(2): 227. CrossRef
The independent effect of exercise on biopsy proven non-alcoholic fatty liver disease: A systematic review Young-Joo Jin Clinical and Molecular Hepatology.2023; 29(2): 414. CrossRef
Hepatocellular carcinoma surveillance in non-alcoholic fatty liver disease – who and how? Margaret LP Teng, Darren Jun Hao Tan, Cheng Han Ng, Daniel Q. Huang Clinical and Molecular Hepatology.2023; 29(2): 404. CrossRef
The effect of moderate alcohol consumption on nonalcoholic fatty liver disease Ji-Won Park, Ki Tae Suk Clinical and Molecular Hepatology.2023; 29(2): 408. CrossRef
Screening strategies for non-alcoholic fatty liver disease: a holistic approach is needed Philipp Kasper, Münevver Demir, Hans-Michael Steffen Clinical and Molecular Hepatology.2023; 29(2): 390. CrossRef
Global burden of primary liver cancer and its association with underlying aetiologies, sociodemographic status, and sex differences from 1990–2019: A DALY-based analysis of the Global Burden of Disease 2019 study Sungchul Choi, Beom Kyung Kim, Dong Keon Yon, Seung Won Lee, Han Gyeol Lee, Ho Hyeok Chang, Seoyeon Park, Ai Koyanagi, Louis Jacob, Elena Dragioti, Joaquim Radua, Jae Il Shin, Seung Up Kim, Lee Smith Clinical and Molecular Hepatology.2023; 29(2): 433. CrossRef
The growing burden of non-alcoholic fatty liver disease on mortality Ju-Yeon Cho, Won Sohn Clinical and Molecular Hepatology.2023; 29(2): 374. CrossRef
Impact of metabolic factors on risk of cardiovascular disease in nondiabetic metabolic dysfunction-associated fatty liver disease Min Kyu Kang, Yu Rim Lee, Se Young Jang, Won Young Tak, Young Oh Kweon, Jeong Eun Song, Rohit Loomba, Soo Young Park, Jung Gil Park Hepatology International.2023; 17(3): 626. CrossRef
Genetic association study identifies genetic variants for non-alcoholic fatty liver without comorbidities in the Korean population Yeon Jun Kim, Yoon Shin Cho Genes & Genomics.2023; 45(7): 847. CrossRef
Association between the fatty liver index and the risk of fracture among individuals over the age of 50 years: a nationwide population-based study Goh Eun Chung, Eun Ju Cho, Min Joo Kim, Jeong-Ju Yoo, Yuri Cho, Kyu-na Lee, Kyungdo Han, Yoon Jun Kim, Jung-Hwan Yoon, Dong Wook Shin, Su Jong Yu Frontiers in Endocrinology.2023;[Epub] CrossRef
Therapeutic Mechanisms and Clinical Effects of Glucagon-like Peptide 1 Receptor Agonists in Nonalcoholic Fatty Liver Disease Han Ah Lee, Hwi Young Kim International Journal of Molecular Sciences.2023; 24(11): 9324. CrossRef
Low‐quality muscle mass rather than normal‐quality muscle mass determines fibrosis progression in biopsy‐proven NAFLD Yun Kyu Lee, Bo Kyung Koo, Sae Kyung Joo, Dong Hyeon Lee, Heejoon Jang, Jee Won Chai, Myoung Seok Lee, Si Won Jang, Young Ho So, Jeong Hwan Park, Mee Soo Chang, Won Kim Alimentary Pharmacology & Therapeutics.2023; 58(3): 322. CrossRef
Clinical and histologic factors associated with discordance between steatosis grade derived from histology vs. MRI‐PDFF in NAFLD Beom K. Kim, Nicole Bernstein, Daniel Q. Huang, Nobuharu Tamaki, Kento Imajo, Masato Yoneda, Nancy Sutter, Jinho Jung, Khang Nguyen, Leyna Nguyen, Tracy Le, Egbert Madamba, Lisa Richards, Mark A. Valasek, Cynthia Behling, Claude B. Sirlin, Atsushi Nakajim Alimentary Pharmacology & Therapeutics.2023; 58(2): 229. CrossRef
Changes in liver stiffness values assessed using transient elastography in chronic hepatitis B patients treated with tenofovir disoproxil fumarate: a prospective observational study Heejin Cho, Yun Bin Lee, Yeonjung Ha, Young Eun Chon, Mi Na Kim, Joo Ho Lee, Hana Park, Kyu Sung Rim, Seong Gyu Hwang BMC Gastroenterology.2023;[Epub] CrossRef
Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma Byeong Geun Song, Sung Chul Choi, Myung Ji Goh, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Seung Woon Paik JHEP Reports.2023; 5(9): 100810. CrossRef
Transient elastography with controlled attenuation parameter versus two-dimensional shear wave elastography with attenuation imaging for the evaluation of hepatic steatosis and fibrosis in NAFLD Jung Wook Seo, Youe Ree Kim, Jong Keon Jang, So Yeon Kim, Young Youn Cho, Eun Sun Lee, Dong Ho Lee Ultrasonography.2023; 42(3): 421. CrossRef
Serum resistin and the risk for hepatocellular carcinoma in diabetic patients Mona Mohamed Ibrahim Abdalla World Journal of Gastroenterology.2023; 29(27): 4271. CrossRef
Fibrotic Burden in the Liver Differs Across Metabolic Dysfunction-Associated Fatty Liver Disease Subtypes Tae Seop Lim, Ho Soo Chun, Soon Sun Kim, Ja Kyung Kim, Minjong Lee, Hyo Jung Cho, Seung Up Kim, Jae Youn Cheong Gut and Liver.2023; 17(4): 610. CrossRef
The correlation between NAFLD and serum uric acid to serum creatinine ratio Jangwon Choi, Hyun Joe, Jung-Eun Oh, Yong-Jin Cho, Hwang-Sik Shin, Nam Hun Heo, Gulali Aktas PLOS ONE.2023; 18(7): e0288666. CrossRef
Association between daily aspirin therapy and risk of hepatocellular carcinoma according to metabolic risk factor burden in non‐cirrhotic patients with chronic hepatitis B Cheol‐Hyung Lee, Yun Bin Lee, Hyemi Moon, Jong‐Won Chung, Eun Ju Cho, Jeong‐Hoon Lee, Su Jong Yu, Yoon Jun Kim, Juneyoung Lee, Jung‐Hwan Yoon Alimentary Pharmacology & Therapeutics.2023; 58(7): 704. CrossRef
Aerobic and Resistance Exercise: Synergistic Influence for Nonalcoholic Fatty Liver Disease Ho Soo Chun Gut and Liver.2023; 17(4): 485. CrossRef
KASL clinical practice guidelines for management of autoimmune hepatitis 2022
Clinical and Molecular Hepatology.2023; 29(3): 542. CrossRef
Comments on Relationship between the High Fatty Liver Index and Risk of Fracture: Reply Min-Ji Kim, Jae-Hyung Roh, Jae-Han Jeon Gut and Liver.2023; 17(4): 663. CrossRef
Regression of nonalcoholic fatty liver disease is associated with reduced risk of incident diabetes: A longitudinal cohort study Dong Hyun Sinn, Danbee Kang, Eliseo Guallar, Sung Chul Choi, Yun Soo Hong, Yewan Park, Juhee Cho, Geum-Youn Gwak, Ahmed Mustafa Rashid PLOS ONE.2023; 18(7): e0288820. CrossRef
Effect of 12-week intermittent calorie restriction compared to standard of care in patients with nonalcoholic fatty liver disease: a randomized controlled trial Han Ah Lee, Hyeyoung Moon, Yuri Kim, Hye Ah Lee, Hwi Young Kim Trials.2023;[Epub] CrossRef
Associations of Serum Uric Acid Level With Liver Enzymes, Nonalcoholic Fatty Liver Disease, and Liver Fibrosis in Korean Men and Women: A Cross-Sectional Study Using Nationally Representative Data Jun Myong Lee, Hye Won Kim, So Young Heo, Kyung Yi Do, Jun Deok Lee, Seul Ki Han, Soon Koo Baik, Moon Young Kim, Sei-Jin Chang Journal of Korean Medical Science.2023;[Epub] CrossRef
Statins for treatment of fatty liver disease: Recent advances Xiao-Hui Fang, Cai-E Wang, Jiao Deng, Xing-Shun Qi World Chinese Journal of Digestology.2023; 31(16): 659. CrossRef
MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study Eugene Han, Ho Soo Chun, Yong‐ho Lee, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Byung‐Wan Lee, Eun Seok Kang, Bong‐Soo Cha, Sang Hoon Ahn, Seung Up Kim Journal of Gastroenterology and Hepatology.2023; 38(9): 1598. CrossRef
The effect of hepatic steatosis on 18F-FDG uptake in PET-CT examinations of cancer Egyptian patients Magdi A. Ali, Eman El-Abd, Mohamed Morsi, Mohamed M. El Safwany, Mohamed Z. El-Sayed European Journal of Hybrid Imaging.2023;[Epub] CrossRef
Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity Gi-Ae Kim, Joon Ho Moon, Won Kim Clinical and Molecular Hepatology.2023; 29(4): 831. CrossRef
Real-World Epidemiology, Treatment Patterns, and Disease Burden of Chronic Hepatitis B and HDV Co-Infection in South Korea Yuri Cho, SeongBeom Park, SeonYoung Park, WonJung Choi, Book Kim, Helin Han Infectious Diseases and Therapy.2023; 12(10): 2387. CrossRef
Association between waist circumference trajectories and incident non-alcoholic fatty liver disease Jun-Hyuk Lee, Soyoung Jeon, Hye Sun Lee, Yu-Jin Kwon Obesity Research & Clinical Practice.2023; 17(5): 398. CrossRef
Overview and prospect of NAFLD: Significant roles of nutrients and dietary patterns in its progression or prevention Tianyu Mao, Yiwen Sun, Xinyi Xu, Kang He Hepatology Communications.2023;[Epub] CrossRef
Approach to Fatty Liver Disease in Patients with Type 2 Diabetes Ji Cheol Bae The Journal of Korean Diabetes.2023; 24(3): 107. CrossRef
Lactobacillus plantarum ameliorates NASH-related inflammation by upregulating l-arginine production Dong Yun Kim, Jun Yong Park, Heon Yung Gee Experimental & Molecular Medicine.2023; 55(11): 2332. CrossRef
Magnetic resonance elastography-based prediction model for hepatic decompensation in NAFLD: A multicenter cohort study Beom Kyung Kim, Jaclyn Bergstrom, Rohan Loomba, Nobuharu Tamaki, Namiki Izumi, Atsushi Nakajima, Ramazan Idilman, Mesut Gumussoy, Digdem K. Oz, Ayse Erden, Emily Truong, Ju Dong Yang, Mazen Noureddin, Alina M. Allen, Rohit Loomba, Veeral Ajmera Hepatology.2023; 78(6): 1858. CrossRef
Association between total body muscle percentage and prevalence of non-alcoholic fatty liver disease in Korean adults findings from an 18-year follow-up: a prospective cohort study Byoung Chan Ahn, Chul Yong Park, Jung Hee Hong, Ki Ook Baek Journal of Yeungnam Medical Science.2023; 40(Suppl): S47. CrossRef
The Association of Perfluoroalkyl Substance Exposure and a Serum Liver Function Marker in Korean Adults Jisuk Yun, Soon-Chan Kwon Toxics.2023; 11(12): 965. CrossRef
Alcohol consumption and the risk of liver disease: a nationwide, population-based study Sang Yi Moon, Minkook Son, Yeo Wool Kang, Myeongseok Koh, Jong Yoon Lee, Yang Hyun Baek Frontiers in Medicine.2023;[Epub] CrossRef
Lifestyle of patients with non-alcoholic fatty liver disease: assessment of dietary habits and physical activity T.S. Krolevets, M.I. Syrovenko, M.A. Livzan Russian Journal of Evidence-Based Gastroenterology.2023; 12(4): 43. CrossRef
Association of Hepatic Fat Deposition and Severity of Acanthosis Nigricans in Children and Adolescents with Obesity Junhyung Lee, Hye-ji An, Young-Gyun Seo, Hong Ji Song, Hye-Mi Noh, Yu-Jin Paek, Kyung Hee Park Korean Journal of Family Practice.2023; 13(4): 240. CrossRef
Advanced liver fibrosis measured by transient elastography predicts chronic kidney disease development in individuals with non-alcoholic fatty liver disease Chan-Young Jung, Geun Woo Ryu, Hyung Woo Kim, Sang Hoon Ahn, Seung Up Kim, Beom Seok Kim Diabetologia.2022; 65(3): 518. CrossRef
Long-term effects of the changes in hepatic steatosis status on the risk of incident type 2 diabetes mellitus: A 15-year community-based prospective cohort study Seung Min Chung, Min Kyu Kang, Jinho Jung, Ji Sung Yoon, Kyu Chang Won, Hyoung Woo Lee, Rohit Loomba, Jung Gil Park, Jun Sung Moon Diabetes Research and Clinical Practice.2022; 184: 109208. CrossRef
Benefit of Antiviral Therapy for HBV-Related HCC with Undetectable HBV DNA Is Still Dubious Suprabhat Giri, Harish Darak, Sunil Kasturi Digestive Diseases and Sciences.2022; 67(10): 4962. CrossRef
Gut Microbiome in Non-Alcoholic Fatty Liver Disease: From Mechanisms to Therapeutic Role Haripriya Gupta, Byeong-Hyun Min, Raja Ganesan, Yoseph Asmelash Gebru, Satya Priya Sharma, Eunju Park, Sung-Min Won, Jin-Ju Jeong, Su-Been Lee, Min-Gi Cha, Goo-Hyun Kwon, Min-Kyo Jeong, Ji-Ye Hyun, Jung-A. Eom, Hee-Jin Park, Sang-Jun Yoon, Mi-Ran Choi, Do Biomedicines.2022; 10(3): 550. CrossRef
Aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B with or without cirrhosis Heejoon Jang, Yun Bin Lee, Hyemi Moon, Jong‐Won Chung, Joon Yeul Nam, Eun Ju Cho, Jeong‐Hoon Lee, Su Jong Yu, Yoon Jun Kim, Juneyoung Lee, Jung‐Hwan Yoon Hepatology.2022; 76(2): 492. CrossRef
The Phase 2 Study to Evaluate Efficacy and Safety of Lanifibranor in Patients with Nonalcoholic Steatohepatitis: Back in the Spotlight? Sae Hwan Lee The Korean Journal of Gastroenterology.2022; 79(3): 138. CrossRef
Metabolic dysfunction-associated fatty liver disease and risk of incident chronic kidney disease: A nationwide cohort study Chan-Young Jung, Hee Byung Koh, Keun Hyung Park, Young Su Joo, Hyung Woo Kim, Sang Hoon Ahn, Jung Tak Park, Seung Up Kim Diabetes & Metabolism.2022; 48(4): 101344. CrossRef
MAFLD enhances clinical practice for liver disease in the Asia-Pacific region Takumi Kawaguchi, Tsubasa Tsutsumi, Dan Nakano, Mohammed Eslam, Jacob George, Takuji Torimura Clinical and Molecular Hepatology.2022; 28(2): 150. CrossRef
PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients Naomi F. Lange, Vanessa Graf, Cyrielle Caussy, Jean-François Dufour International Journal of Molecular Sciences.2022; 23(8): 4305. CrossRef
Prevalence trends of non-alcoholic fatty liver disease among young men in Korea: A Korean military population-based cross-sectional study Jaejun Lee, Taeyun Kim, Hyun Yang, Si Hyun Bae Clinical and Molecular Hepatology.2022; 28(2): 196. CrossRef
Recent Epidemiology and Risk Factors of Nonalcoholic Fatty Liver Disease Youn Huh, Yoon Jeong Cho, Ga Eun Nam Journal of Obesity & Metabolic Syndrome.2022; 31(1): 17. CrossRef
Gamma‐glutamyl transpeptidase dynamics as a biomarker for advanced fibrosis in non‐alcoholic fatty liver disease Yeonjung Ha, Young Eun Chon, Mi Na Kim, Joo Ho Lee, Seong Gyu Hwang Journal of Gastroenterology and Hepatology.2022; 37(8): 1624. CrossRef
The Importance of Metabolic Syndrome Status for the Risk of Non-Viral Hepatocellular Carcinoma: A Nationwide Population-Based Study Yuri Cho, Eun Ju Cho, Jeong-Ju Yoo, Young Chang, Goh Eun Chung, In Young Choi, Sang-Hyun Park, Kyungdo Han, Yoon Jun Kim, Jung-Hwan Yoon, Dong Wook Shin, Su Jong Yu Frontiers in Oncology.2022;[Epub] CrossRef
Association of Low Skeletal Muscle Mass with the Phenotype of Lean Non-Alcoholic Fatty Liver Disease Jun-Hyeon Byeon, Min-Kyu Kang, Min-Cheol Kim Healthcare.2022; 10(5): 850. CrossRef
Association of Metabolomic Change and Treatment Response in Patients with Non-Alcoholic Fatty Liver Disease Kwang Seob Lee, Yongin Cho, Hongkyung Kim, Hyunkyeong Hwang, Jin Won Cho, Yong-ho Lee, Sang-Guk Lee Biomedicines.2022; 10(6): 1216. CrossRef
Risk of liver fibrosis in patients with prediabetes and diabetes mellitus Jongsin Park, Heon-Ju Kwon, Won Sohn, Ju-Yeon Cho, Soo Jin Park, Yoosoo Chang, Seungho Ryu, Byung Ik Kim, Yong Kyun Cho, Chen-Hua Liu PLOS ONE.2022; 17(6): e0269070. CrossRef
Exercise reduces the risk of chronic kidney disease in individuals with nonalcoholic fatty liver disease: A nationwide cohort study Chan-Young Jung, Ho Soo Chun, Minjong Lee, Hee Byung Koh, Keun Hyung Park, Young Su Joo, Hyung Woo Kim, Sang Hoon Ahn, Jung Tak Park, Seung Up Kim Diabetes & Metabolism.2022; 48(5): 101362. CrossRef
Nonalcoholic fatty liver disease and accelerated loss of skeletal muscle mass: A longitudinal cohort study Dong Hyun Sinn, Danbee Kang, Mira Kang, Eliseo Guallar, Yun Soo Hong, Kyung Hyun Lee, Jiyeon Park, Juhee Cho, Geum‐Youn Gwak Hepatology.2022; 76(6): 1746. CrossRef
Short-term outcome of bariatric surgery on nonalcoholic fatty liver disease: a Korean perspective Ki Hyun Kim, Yoonhong Kim, Kwang Il Seo, Kyung Won Seo Annals of Surgical Treatment and Research.2022; 102(6): 353. CrossRef
A Case Report of Nonalcoholic Fatty Liver Disease with Obesity and Dyslipidemia Eujin Kim, Cho-Hyun Hwang, Juyoung Lee, Eungyeong Jang, Youngchul Kim, Jang-Hoon Lee The Journal of Internal Korean Medicine.2022; 43(2): 184. CrossRef
Lean non-alcoholic fatty liver disease (Lean-NAFLD) and the development of metabolic syndrome: a retrospective study Wenting Wang, Jianping Ren, Wenzhao Zhou, Jinyu Huang, Guomin Wu, Fenfang Yang, Shuang Yuan, Juan Fang, Jing Liu, Yao Jin, Haiyang Qi, Yuyang Miao, Yanna Le, Cenhong Ge, Xiantao Qiu, JinJing Wang, Ping Huang, Zixin Liu, Sheng Wang Scientific Reports.2022;[Epub] CrossRef
Obstructive Sleep Apnea and Nonalcoholic Fatty Liver Disease in the General Population: A Cross-Sectional Study Using Nationally Representative Data Taeyun Kim, Hyunji Choi, Jaejun Lee, Jehun Kim International Journal of Environmental Research and Public Health.2022; 19(14): 8398. CrossRef
Fatty Liver Disease and Cardiovascular Risk: Impact of Metabolic Dysfunctions Jung Il Lee Gut and Liver.2022; 16(4): 497. CrossRef
Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases Han Ah Lee, Young Chang, Pil Soo Sung, Eileen L. Yoon, Hye Won Lee, Jeong-Ju Yoo, Young-Sun Lee, Jihyun An, Do Seon Song, Young Youn Cho, Seung Up Kim, Yoon Jun Kim Clinical and Molecular Hepatology.2022; 28(3): 425. CrossRef
Real‐world clinical features, health‐care utilization, and economic burden in decompensated cirrhosis patients: A national database Hankil Lee, Beom Kyung Kim Journal of Gastroenterology and Hepatology.2022; 37(11): 2154. CrossRef
Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD Beom Kyung Kim, Nobuharu Tamaki, Kento Imajo, Masato Yoneda, Nancy Sutter, Jinho Jung, Tuo Lin, Xin M. Tu, Jaclyn Bergstrom, Khang Nguyen, Leyna Nguyen, Tracy Le, Egbert Madamba, Lisa Richards, Mark A. Valasek, Cynthia Behling, Claude B. Sirlin, Atsushi N Journal of Hepatology.2022; 77(6): 1482. CrossRef
Magnetic resonance imaging improves stratification of fibrosis and steatosis in patients with chronic liver disease Han Ah Lee, Seung-seob Kim, Jin-Young Choi, Yeon Seok Seo, Beom Jin Park, Ki Choon Sim, Seung Up Kim Abdominal Radiology.2022; 47(11): 3733. CrossRef
Fatty Liver Change in Korean Adults in a Systematic Social Distancing System Amid the COVID-19 Pandemic: A Multicenter Analysis Ji-Hee Haam, Yang-Im Hur, Young-Sang Kim, Kyoung-Kon Kim, Jee-Hyun Kang, Hae-Jin Ko, Yoon Jeong Cho, Hye-In Choi, Kyu Rae Lee, Jung Ha Park, Soo Hyun Cho, Jong-Koo Kim, Taesic Lee, Myung-Jae Seo, Yeong Sook Yoon, Yoobin Seo, Ga Eun Nam, Sun Hyun Kim International Journal of Environmental Research and Public Health.2022; 19(16): 10444. CrossRef
Association between grip strength and non-alcoholic fatty liver disease: A systematic review and meta-analysis Liu Han, Shifeng Fu, Jianglei Li, Deliang Liu, Yuyong Tan Frontiers in Medicine.2022;[Epub] CrossRef
Correlation between shift work and non-alcoholic fatty liver disease among male workers in the steel manufacturing company of Korea: a cross-sectional study Kiseok Kim, Yong-Jin Lee, Soon-Chan Kwon, Young-Sun Min, Hyun Kyo Lee, Gwangin Baek, Sang Hyeon Kim, Eun-Chul Jang Annals of Occupational and Environmental Medicine.2022;[Epub] CrossRef
Radiomics Analysis of Magnetic Resonance Proton Density Fat Fraction for the Diagnosis of Hepatic Steatosis in Patients With Suspected Non-Alcoholic Fatty Liver Disease Ki Choon Sim, Min Ju Kim, Yongwon Cho, Hyun Jin Kim, Beom Jin Park, Deuk Jae Sung, Na Yeon Han, Yeo Eun Han, Tae Hyung Kim, Yoo Jin Lee Journal of Korean Medical Science.2022;[Epub] CrossRef
Bioelectrical Impedance Analysis Can Be an Effective Tool for Screening Fatty Liver in Patients with Suspected Liver Disease Jin Wook Choi, Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim Healthcare.2022; 10(11): 2268. CrossRef
Tenofovir alafenamide alleviates nonalcoholic steatohepatitis in mice by blocking the phosphorylation of AKT in intrahepatic mononuclear phagocytes Pu Reun Roh, Sung Min Kim, Byung-Yoon Kang, Kyoung Do Mun, Jong Geun Park, Min Woo Kang, Wonhee Hur, Ji Won Han, Heechul Nam, Seung Kew Yoon, Pil Soo Sung Biomedicine & Pharmacotherapy.2022; 156: 113952. CrossRef
Accuracy of Noninvasive Scoring Systems in Assessing Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis Sangsoo Han, Miyoung Choi, Bora Lee, Hye-Won Lee, Seong Hee Kang, Yuri Cho, Sang Bong Ahn, Do Seon Song, Dae Won Jun, Jieun Lee, Jeong-Ju Yoo Gut and Liver.2022; 16(6): 952. CrossRef
The usefulness of metabolic score for insulin resistance for the prediction of incident non-alcoholic fatty liver disease in Korean adults Jun-Hyuk Lee, Kyongmin Park, Hye Sun Lee, Hoon-Ki Park, Jee Hye Han, Sang Bong Ahn Clinical and Molecular Hepatology.2022; 28(4): 814. CrossRef
Screening and prediction of nonalcoholic fatty liver disease using a peripheral insulin resistance index: Potential benefits and limitations Soon Sun Kim, Jae Youn Cheong Clinical and Molecular Hepatology.2022; 28(4): 802. CrossRef
Association between small dense LDL levels and hepatic fibrosis in patients with nonalcoholic fatty liver disease Sun Young Kim, Subin Mun, Jung Hwan Yu, Young-Joo Jin, Young Ju Suh, Sang-Heon Cho, Jin-Woo Lee Medicine.2022; 101(37): e30527. CrossRef
A Review of Research Trends in Traditional Korean Medicine for Nonalcoholic Fatty Liver Disease Na-yeon Kim, Mi-jung Yoon, Hong-sik Choi, Seung-mo Kim, Sang-chan Kim, Kyung-soon Kim The Journal of Internal Korean Medicine.2022; 43(4): 680. CrossRef
Non-alcoholic fatty liver disease and risk of dementia: Unmet need for a pooled analysis of cohort studies Seogsong Jeong, Won Kim, Sang Min Park Clinical and Molecular Hepatology.2022; 28(4): 933. CrossRef
Suboptimal Performance of Hepatocellular Carcinoma Prediction Models in Patients with Hepatitis B Virus-Related Cirrhosis Jae Lee, Tae Lim, Hye Lee, Seung Kim, Jun Park, Do Kim, Sang Ahn, Hyun Lee, Jung Lee, Ja Kim, In Min, Beom Kim Diagnostics.2022; 13(1): 3. CrossRef
Terpenoids: Natural Compounds for Non-Alcoholic Fatty Liver Disease (NAFLD) Therapy Pengyu Yao, Yajuan Liu Molecules.2022; 28(1): 272. CrossRef
The Evidence Surrounding Non-Alcoholic Fatty Liver Disease in Individuals with Cancer: A Systematic Literature Review Elena S. George, Surbhi Sood, Nicole Kiss, Robin M. Daly, Amanda J. Nicoll, Stuart K. Roberts, Brenton J. Baguley Current Oncology.2022; 30(1): 48. CrossRef
Prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) in Korean Patients Undergoing Bariatric Surgery Ki Hyun Kim, Yoonhong Kim, Kwang Il Seo, Kyung Won Seo Journal of Metabolic and Bariatric Surgery.2022; 11(2): 63. CrossRef
Fatty Liver Index for Predicting Nonalcoholic Fatty Liver Disease in an Asymptomatic Korean Population Eun-Ju Cho, Gu-Cheol Jung, Min-Sun Kwak, Jong-In Yang, Jeong-Yoon Yim, Su-Jong Yu, Goh-Eun Chung Diagnostics.2021; 11(12): 2233. CrossRef
Association between Fasting Ketonuria and Advanced Liver Fibrosis in Non-Alcoholic Fatty Liver Disease Patients without Prediabetes and Diabetes Mellitus Kiyoung Lim, Minkyu Kang, Junggil Park Nutrients.2021; 13(10): 3400. CrossRef
Evaluation of the severity of nonalcoholic fatty liver disease through analysis of serum exosomal miRNA expression Jeong-An Gim, Soo Min Bang, Young-Sun Lee, Yoonseok Lee, Sun Young Yim, Young Kul Jung, Hayeon Kim, Baek-Hui Kim, Ji Hoon Kim, Yeon Seok Seo, Hyung Joon Yim, Jong Eun Yeon, Soon Ho Um, Kwan Soo Byun, Matias A. Avila PLOS ONE.2021; 16(8): e0255822. CrossRef
Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis Yuan Zhu, Jiao Xu, Dong Zhang, Xingyu Mu, Yi Shi, Shangtao Chen, Zengxiang Wu, Shuangqing Li Frontiers in Endocrinology.2021;[Epub] CrossRef
Effect of Nutrition Education in NAFLD Patients Undergoing Simultaneous Hyperlipidemia Pharmacotherapy: A Randomized Controlled Trial Won Myung Lee, Jea Hurn Bae, Young Chang, Sae Hwan Lee, Ji Eun Moon, Soung Won Jeong, Jae Young Jang, Sang Gyune Kim, Hong Soo Kim, Jeong-Ju Yoo, Young Seok Kim Nutrients.2021; 13(12): 4453. CrossRef
Liver Stiffness-Based Risk Prediction Model for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease Jae Seung Lee, Dong Hyun Sinn, Soo Young Park, Hye Jung Shin, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Joo Hyun Oh, Jung Il Lee, Seung Up Kim Cancers.2021; 13(18): 4567. CrossRef
Se Ri Ryu, Jeong-Ju Yoo, Seong Hee Kang, Soung Won Jeong, Moon Young Kim, Young Kyu Cho, Young Chang, Sang Gyune Kim, Jae Young Jang, Young Seok Kim, Soon Koo Baik, Yong Jae Kim, Su Yeon Park, Baigal Baymbajav
Clin Mol Hepatol 2021;27(1):197-206. Published online December 3, 2020
Background/Aims The hepatic venous pressure gradient (HVPG) reflects portal hypertension, but its measurement is invasive. Transient elastography (TE) is a noninvasive method for evaluating liver stiffness (LS). We investigated the correlation between the value of LS, LS to platelet ratio (LPR), LS-spleen diameter-to-platelet ratio score (LSPS) and HVPG according to the etiology of cirrhosis, especially focused on alcoholic cirrhosis.
Methods Between January 2008 and March 2017, 556 patients who underwent HVPG and TE were consecutively enrolled. We evaluated LS, LPR, and LSPS according to the etiology of cirrhosis and analyzed their correlations with HVPG.
Results The LS value was higher in patients with alcoholic cirrhosis than viral cirrhosis based on the HVPG (43.5 vs. 32.0 kPa, P<0.001). There were no significant differences in the LPR or LSPS between alcoholic and viral cirrhosis groups, and the areas under the curves for the LPR and LSPS in subgroups according to HVPG levels were not superior to that for LS. In alcoholic cirrhosis, the LS cutoff value for predicting an HVPG ≥10 mmHg was 32.2 kPa with positive predictive value (PPV) of 94.5% and 36.6 kPa for HVPG ≥12 mmHg with PPV of 91.0%.
Conclusions The LS cutoff value should be determined separately for patients with alcoholic and viral cirrhosis. In alcoholic cirrhosis, the LS cutoff values were 32.2 and 36.6 kPa for predicting an HVPG ≥10 and ≥12 mmHg, respectively. However, there were no significant differences in the LPR or LSPS between alcoholic and viral cirrhosis groups.
Citations
Citations to this article as recorded by
Assessment of liver stiffness measurement-related markers in predicting liver-related events in viral cirrhosis with clinically significant portal hypertension Yan-Qiu Li, Yong-Qi Li, Jin-Ze Li, Bing-Bing Zhu, Yu Lu, Ying Feng, Xian-Bo Wang World Journal of Hepatology.2025;[Epub] CrossRef
Effect of tenofovir alafenamide on immune function and long-term prognosis in patients with chronic hepatitis B-related liver cirrhosis using two-dimensional ultrasound evaluation Yueran Wu, Xia Li, Xiaopeng Yang, Lijun Lin, Biying Zou, Yulin Chen Journal of Radiation Research and Applied Sciences.2025; 18(4): 102041. CrossRef
Analysis of Factors Influencing Prognosis and Assessment of 60 Cases of Decompensated Cirrhotic Patients with Portal Hypertension Xue Li, Shi Liu, Jin Li, Ning Liu, Hui Li, An Ge, Liang Wang, Xie Dong, Hui Wang, Ju Liu, Lin Zhang, Hao Dong Zhang, Wei Gou International Journal of General Medicine.2024; Volume 17: 1493. CrossRef
Enhancing liver cirrhosis varices and CSPH risk prediction with spleen stiffness measurement using 100-Hz probe Jeong-Ju Yoo, Sun Ah Maeng, Young Chang, Sae Hwan Lee, Soung Won Jeong, Jae Young Jang, Gab Jin Cheon, Young Seok Kim, Hong Soo Kim, Sang Gyune Kim Scientific Reports.2024;[Epub] CrossRef
Non-invasive tests-based risk stratification: Baveno VII and beyond Georg Semmler, Mathias Jachs, Mattias Mandorfer Clinical and Molecular Hepatology.2023; 29(1): 105. CrossRef
The rise of non-invasive tools in the diagnosis of portal hypertension: Validation of the Baveno VII consensus Jeong-Ju Yoo, Sang Gyune Kim Clinical and Molecular Hepatology.2023; 29(1): 102. CrossRef
Noninvasive risk assessment of hepatic decompensation in patients with hepatitis B virus‐related liver cirrhosis David Sooik Kim, Beom Kyung Kim, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Nikolaos Pyrsopoulos, Seung Up Kim Journal of Gastroenterology and Hepatology.2023; 38(8): 1372. CrossRef
Validation of non‐invasive diagnosis of CSPH in patients with compensated advanced chronic liver disease according to Baveno VII Byeong Geun Song, Myung Ji Goh, Wonseok Kang, Geum‐Youn Gwak, Yong‐Han Paik, Moon Seok Choi, Joon Hyeok Lee, Seung Woon Paik, Dong Hyun Sinn Liver International.2023; 43(9): 1966. CrossRef
Validation of PH and Varices Risk Scores for Prediction of High-Risk Esophageal Varix and Bleeding in Patients with B-Viral Cirrhosis Seunghwan Shin, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim Diagnostics.2022; 12(2): 441. CrossRef
Diagnostic accuracy of transient elastography in diagnosing clinically significant portal hypertension in patients with chronic liver disease: a systematic review and meta-analysis Ashish Kumar, Hitoshi Maruyama, Anil Arora, Praveen Sharma, Shrihari Anil Anikhindi, Naresh Bansal, Mandhir Kumar, Piyush Ranjan, Munish Sachdeva, Shivam Khare Journal of Medical Ultrasonics.2022; 49(3): 333. CrossRef
Influence of portal vein occlusion on portal flow and liver elasticity in an animal model Simon Chatelin, Raoul Pop, Céline Giraudeau, Khalid Ambarki, Ning Jin, François Séverac, Elodie Breton, Jonathan Vappou NMR in Biomedicine.2021;[Epub] CrossRef
The Diagnostic Accuracy of LOGIQ S8 and E9 Shear Wave Elastography for Staging Hepatic Fibrosis, in Comparison with Transient Elastography Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim Diagnostics.2021; 11(10): 1817. CrossRef
Background/Aims Liver biopsy (LB) remains the gold standard for the evaluation of liver disease. However, over the past two decades, many noninvasive tests have been developed and utilized in clinical practice as alternatives to LB. The aim of this study was to evaluate the clinical use and safety of LB in the era of noninvasive assessment of liver fibrosis.
Methods This retrospective study included 1,944 consecutive cases of LB performed between 2001 and 2018 in a tertiary hospital. All of the LBs were conducted under ultrasonography guidance with 18-gauge cutting needles.
Results LBs were performed an average of approximately 108 times per year during the study period. Chronic hepatitis B (25.3%) and suspected malignancy (20.5%) were the two most common indications for LB. The use of LB for nonalcoholic fatty liver disease increased from 8.1% to 17.2% in the past 5 years compared to the last 10 years, while that for viral hepatitis decreased from 40.3% to 18.9%. Discordance rate between the suspected diagnosis and the final diagnosis was 2.6% (51 cases). The overall rate of major adverse events was 0.05% (one case), which involved delayed bleeding at the biopsy site. Liver cirrhosis was observed in 563 cases (28.9%), and the presence of cirrhosis did not affect the frequency of complications (P=0.289).
Conclusions LB is widely used in clinical practice as an irreplaceable diagnostic tool, even in the era of noninvasiveness. Ultrasonography-guided LB can be performed safely in patients with liver cirrhosis.
Citations
Citations to this article as recorded by
Surgeon-led Point-of-care Ultrasound-guided Thoracic Biopsy: A new paradigm in efficient diagnosis and resource-sparing care Vaibhav Gupta, Stephen D. Gowing, Rudra Pandya, Lawrence Tan, Richard Y. Liu, Sadeesh K. Srinathan, Biniam Kidane The Journal of Thoracic and Cardiovascular Surgery.2025; 170(2): 369. CrossRef
Current Trends and Impact of Liver Biopsy on Survival in Hepatocellular Carcinoma: A Korean Multicenter Analysis Seong Joon Chun, Jeong-Ju Yoo, Sang Gyune Kim, Young-Seok Kim Diagnostics.2025; 15(7): 818. CrossRef
Association of preablation tumor biopsy and long-term outcomes of colorectal liver oligometastases Wenqi Chen, Jianming Li, Lu Li, Rui Cui, Guangjian Liu, Ping Liang, Jie Yu European Journal of Radiology.2025; 187: 112089. CrossRef
A review of image guidance and localization methods for liver puncture robots Yongde Zhang, Jiabin Yang, Xuequan Huang, Chuang He Journal of Robotic Surgery.2025;[Epub] CrossRef
Deep Learning to Localize Photoacoustic Sources in Three Dimensions: Theory and Implementation Mardava R. Gubbi, Muyinatu A. Lediju Bell IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control.2025; 72(6): 786. CrossRef
Improving diagnostic accuracy in cirrhotic patients: a comprehensive multicenter analysis of contrast-enhanced ultrasound-guided biopsy in a large cohort of 2056 patients Binbin Jiang, Xiang Jing, Yuxiang Wang, Xiaolin Zhu, Jing Wang, Ruiqing Du, Bin Lv, Kefeng Wang, Zhixiang Gao, Kun Yan La radiologia medica.2025; 130(8): 1297. CrossRef
Serum α-SMA is a potential noninvasive biomarker of liver fibrosis Irina Cardoso-Lezama, Erika Ramos-Tovar, Jaime Arellanes-Robledo, Eduardo E. Vargas-Pozada, Verónica Rocío Vásquez-Garzón, Saúl Villa-Treviño, Pablo Muriel Toxicology Mechanisms and Methods.2024; 34(1): 13. CrossRef
Highest 3-month international normalized ratio (INR): a predictor of bleeding following ultrasound-guided liver biopsy Nhi H. Vo, Mehmet A. Sari, Elena Grimaldi, Emmanuel Berchmans, Michael P. Curry, Muneeb Ahmed, Bettina Siewert, Alexander Brook, Olga R. Brook European Radiology.2024; 34(10): 6416. CrossRef
The Diagnostic Value of Liver Biopsy for Unexplained Liver Dysfunction: A Retrospective Study Ruifang Shi, Fan Yang, Hongli Wu, Yonggang Liu Journal of Multidisciplinary Healthcare.2024; Volume 17: 2399. CrossRef
Clinical significance of exosomal noncoding RNAs in hepatocellular carcinoma: a narrative review Jae Sung Yoo, Min Kyu Kang Journal of Yeungnam Medical Science.2024; 42: 4. CrossRef
Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase Jeong-Ju Yoo, Soo Young Park, Ji Eun Moon, Yu Rim Lee, Han Ah Lee, Jieun Lee, Young Seok Kim, Yeon Seok Seo, Sang Gyune Kim Clinical and Molecular Hepatology.2023; 29(2): 482. CrossRef
Controlled attenuation parameter measured using transient elastography for the noninvasive assessment of macrovesicular steatosis in potential living liver donors Sunyoung Lee, Kyoung Won Kim, So Yeon Kim, Nieun Seo, Gi-Won Song, Sung-Gyu Lee Ultrasonography.2022; 41(1): 164. CrossRef
Noninvasive surrogates are poor predictors of liver fibrosis in patients with Fontan circulation Yu Rim Shin, Seung Up Kim, Sak Lee, Jae Young Choi, Han Ki Park, Jeong Eun Yoo, Young Nyun Park The Journal of Thoracic and Cardiovascular Surgery.2022; 164(4): 1176. CrossRef
MRE-based NASH score for diagnosis of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease Young-Sun Lee, Ji Eun Lee, Hyon-Seung Yi, Young Kul Jung, Dae Won Jun, Ji Hoon Kim, Yeon Seok Seo, Hyung Joon Yim, Baek-hui Kim, Jeong Woo Kim, Chang Hee Lee, Jong Eun Yeon, Juneyoung Lee, Soon Ho Um, Kwan Soo Byun Hepatology International.2022; 16(2): 316. CrossRef
Non-invasive assessment of cirrhosis using multiphasic dual-energy CT iodine maps: correlation with model for end-stage liver disease score Domenico Mastrodicasa, Martin J. Willemink, Celina Duran, Andrea Delli Pizzi, Virginia Hinostroza, Lior Molvin, Mohamed Khalaf, R. Brooke Jeffrey, Bhavik N. Patel Abdominal Radiology.2021; 46(5): 1931. CrossRef
Serum lipocalin-2 is a potential biomarker for the clinical diagnosis of nonalcoholic steatohepatitis Gang Xu, Yu-Min Wang, Miao-Miao Ying, Sui-Dan Chen, Zong-Rui Li, Hong-Lei Ma, Ming-Hua Zheng, Jian Wu, Chunming Ding Clinical and Molecular Hepatology.2021; 27(2): 329. CrossRef
Circulating miRNA is a useful diagnostic biomarker for nonalcoholic steatohepatitis in nonalcoholic fatty liver disease Tae Hyung Kim, Yoonseok Lee, Young-Sun Lee, Jeong-An Gim, Eunjung Ko, Sun Young Yim, Young Kul Jung, SeongHee Kang, Moon Young Kim, Hayeon Kim, Baek-hui Kim, Ji Hoon Kim, Yeon Seok Seo, Hyung Joon Yim, Jong Eun Yeon, Soon Ho Um, Kwan Soo Byun Scientific Reports.2021;[Epub] CrossRef
Evaluation of the severity of nonalcoholic fatty liver disease through analysis of serum exosomal miRNA expression Jeong-An Gim, Soo Min Bang, Young-Sun Lee, Yoonseok Lee, Sun Young Yim, Young Kul Jung, Hayeon Kim, Baek-Hui Kim, Ji Hoon Kim, Yeon Seok Seo, Hyung Joon Yim, Jong Eun Yeon, Soon Ho Um, Kwan Soo Byun, Matias A. Avila PLOS ONE.2021; 16(8): e0255822. CrossRef
Parenchymal Extinction Mimicking Hepatocellular Carcinoma in a Patient with Chronic Hepatitis B-Related Liver Cirrhosis Min Kyu Kang, Joon Hyuk Choi Diagnostics.2021; 11(7): 1171. CrossRef
Controlled attenuation parameter value and the risk of hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy Joo Hyun Oh, Hye Won Lee, Dong Hyun Sinn, Jun Yong Park, Beom Kyung Kim, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Wonseok Kang, Geum-Youn Gwak, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Yong-Han Paik Hepatology International.2021; 15(4): 892. CrossRef
The Diagnostic Accuracy of LOGIQ S8 and E9 Shear Wave Elastography for Staging Hepatic Fibrosis, in Comparison with Transient Elastography Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim Diagnostics.2021; 11(10): 1817. CrossRef
Risk assessment of hepatocellular carcinoma and liver‐related events using ultrasonography and transient elastography in patients with chronic hepatitis B Sung Hwan Yoo, Tae Seop Lim, Hyun Woong Lee, Ja Kyung Kim, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Jung Il Lee, Kwan Sik Lee, Seung Up Kim Journal of Viral Hepatitis.2021; 28(10): 1362. CrossRef
Liver stiffness by magnetic resonance elastography is associated with increased risk of cardiovascular disease in patients with non‐alcoholic fatty liver disease Jung Gil Park, Jinho Jung, Kritin K. Verma, Min Kyu Kang, Egbert Madamba, Scarlett Lopez, Aed Qas Yonan, Amy Liu, Ricki Bettencourt, Claude Sirlin, Rohit Loomba Alimentary Pharmacology & Therapeutics.2021; 53(9): 1030. CrossRef
Is liver biopsy still useful in the era of non-invasive tests? Tae Seop Lim, Ja Kyung Kim Clinical and Molecular Hepatology.2020; 26(3): 302. CrossRef
A Case of Vanishing Bile Duct Syndrome after Drug-Induced Liver Injury Caused by Pelubiprofen Haein Bak, Hayeon Kim, Sieun Lee, Yoonseok Lee, Soo-Min Bang, Young-Sun Lee Yonsei Medical Journal.2020; 61(12): 1060. CrossRef
miRNAs as Potential Biomarkers for Viral Hepatitis B and C Dimitri Loureiro, Issam Tout, Stéphanie Narguet, Sabrina Menasria Benazzouz, Abdellah Mansouri, Tarik Asselah Viruses.2020; 12(12): 1440. CrossRef
Jeong-Ju Yoo, Won Kim, Moon Young Kim, Dae Won Jun, Sang Gyune Kim, Jong-Eun Yeon, Jin Woo Lee, Yong Kyun Cho, Sang Hoon Park, Joo Hyun Sohn, On behalf of the Korean Association for the Study of the Liver (KASL)-Korea Nonalcoholic fatty liver Study Group (KNSG)
Clin Mol Hepatol 2019;25(1):1-11. Published online August 8, 2018
Nonalcoholic fatty liver disease (NAFLD), together with metabolic syndrome and obesity, has shown a rapid increase in prevalence worldwide and is emerging as a major cause of chronic liver disease and liver transplantation. Among the various phenotypes of NAFLD, nonalcoholic steatohepatitis (NASH) is highly likely to progress to development of end-stage liver disease and cardiometabolic disease, resulting in liver-related and non-liver–related mortality. Nonetheless, there is no standardized pharmacotherapy against NASH and many drugs are under development in ongoing clinical trials. To develop a successful anti-NASH drug, it is necessary to select an appropriate target population and treatment outcomes depending on whether the mode of action is anti-metabolic, anti-inflammatory or anti-fibrotic. Recently, innovative surrogate markers have been investigated to replace hard outcomes such as liver histology and mortality and reduce the clinical trial duration. Currently, several drugs with fast track designation are being tested in phase III clinical trials, and many other drugs have moved into phase II clinical trials. Both lean NAFLD and typical obese NAFLD have been extensively studied and genetic variants such as PNPLA3 and TM6SF2 have been identified as significant risk factors for lean NAFLD. In the near future, noninvasive biomarkers and effective targeted therapies for NASH and associated fibrosis are required to develop precision medicine and tailored therapy according to various phenotypes of NAFLD.
Citations
Citations to this article as recorded by
A Literature Review of Glutathione Therapy in Ameliorating Hepatic Dysfunction in Non-Alcoholic Fatty Liver Disease Michelle Thuy Nguyen, Andrew Lian, Frederick Timothy Guilford, Vishwanath Venketaraman Biomedicines.2025; 13(3): 644. CrossRef
Impact of sleeve gastrectomy on the course of metabolic associated fatty liver disease Ragaey Ahmad Eid, Dina Attia, Asmaa Srour Soliman, Eman Ahmed Abd Elmaogod, Eman Mohammed AbdelSalam, Ahmed Mohamed Rashad, Ahmed Safaa Ahmed Sayed, Tamer Mohamed Nabil Indian Journal of Gastroenterology.2025;[Epub] CrossRef
Reply to correspondence 1 on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers” Yoon-su Ha, Won Kim, Seung-Jin Kim Clinical and Molecular Hepatology.2025; 31(2): e226. CrossRef
Correspondence to editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers” Yi-Tong Li, Wei-Qing Shao, Zhen-Mei Chen, Jing Lin, Jin-Hong Chen Clinical and Molecular Hepatology.2025; 31(2): e186. CrossRef
Impact of the FIB4 Index on Pre-sarcopenia in Patients with Metabolic-dysfunction Associated Steatotic Liver Disease Hiroki Nishikawa, Tomohiro Nishikawa, Akira Fukuda, Kosuke Ushiro, Masahiro Matsui, Saori Onishi, Soo Ki Kim, Akira Asai Internal Medicine.2025; 64(21): 3078. CrossRef
Clinical characteristics of lean and non-lean non-alcoholic fatty liver disease: a cross-sectional study Mengyan Xu, Rui Gong, Jiao Xie, Sanping Xu, Shi Wang Nutrition & Metabolism.2025;[Epub] CrossRef
Liver involvement in Gaucher disease in children: A literature review and clinical observations G.V. Volynets, G.B. Movsisyan, A.S. Potapov, A.I. Khavkin, A.V. Nikitin, T.A. Skvortsova, E.A. Morozova, V.M. Rogozhina Russian Journal of Evidence-Based Gastroenterology.2025; 14(2): 78. CrossRef
PNPLA3-Ile148Met and TM6SF2-Glu167Lys increase susceptibility to metabolic dysfunction-associated steatotic liver disease in children Hengpan Yao, Zhiyi Xia, Yijing Liu, MengJun Dong, Kairui Yang, Fang Zhou Frontiers in Endocrinology.2025;[Epub] CrossRef
Recent Progresses on Pathophysiology, Diagnosis, Therapeutic Modalities,
and Management of Non-alcoholic Fatty Liver Disorder Mahdi Barazesh, Sajad Jalili, Morteza Akhzari, Fouzieyeh Faraji, Ebrahim Khorramdin Current Drug Therapy.2024; 19(1): 20. CrossRef
Extracellular Vesicles as Delivery Vehicles for Non-Coding RNAs: Potential Biomarkers for Chronic Liver Diseases Arianna Ferro, Gabriele Saccu, Simone Mattivi, Andrea Gaido, Maria Beatriz Herrera Sanchez, Shafiul Haque, Lorenzo Silengo, Fiorella Altruda, Marilena Durazzo, Sharmila Fagoonee Biomolecules.2024; 14(3): 277. CrossRef
Three-Step Algorithm for Screening High-Risk Group of Metabolic Dysfunction-Associated Steatotic Liver Disease in General Population Joo Hyun Oh, Dae Won Jun Gut and Liver.2024; 18(2): 197. CrossRef
Prognostication in NAFLD: physiological bases, clinical indicators, and newer biomarkers Francesca Terracciani, Andrea Falcomatà, Paolo Gallo, Antonio Picardi, Umberto Vespasiani-Gentilucci Journal of Physiology and Biochemistry.2023; 79(4): 851. CrossRef
Impact of thyroid cancer on the cancer risk in patients with non-alcoholic fatty liver disease or dyslipidemia Joon Ho, Eunhwa Kim, Myeongjee Lee, Inkyung Jung, Young Suk Jo, Jandee Lee Scientific Reports.2023;[Epub] CrossRef
Global incidence and prevalence of nonalcoholic fatty liver disease Margaret LP Teng, Cheng Han Ng, Daniel Q. Huang, Kai En Chan, Darren JH Tan, Wen Hui Lim, Ju Dong Yang, Eunice Tan, Mark D. Muthiah Clinical and Molecular Hepatology.2023; 29(Suppl): S32. CrossRef
Associations between Adipokines and Metabolic Dysfunction-Associated Fatty Liver Disease Using Three Different Diagnostic Criteria Jie Pan, Yijie Ding, Yan Sun, Qiuyan Li, Tianyi Wei, Yingying Gu, Yujia Zhou, Nengzhi Pang, Lei Pei, Sixi Ma, Mengqi Gao, Ying Xiao, De Hu, Feilong Wu, Lili Yang Journal of Clinical Medicine.2023; 12(6): 2126. CrossRef
Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments Sang Bong Ahn Clinical and Molecular Hepatology.2023; 29(Suppl): S150. CrossRef
Non-Traditional Blood Lipid Indices for Metabolism Dysfunction-Associated Fatty Liver Disease Prediction in Non-Obese Type 2 Diabetes Mellitus Qian Gao, Lei Feng, Weiling Zhou, Xiaoli Li, Lanzi Yin, Yuan Wang Diabetes, Metabolic Syndrome and Obesity.2023; Volume 16: 2345. CrossRef
Role of microRNA in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): a comprehensive review Mah I Kan Changez, Maryam Mubeen, Monezahe Zehra, Inara Samnani, Aniqa Abdul Rasool, Anmol Mohan, Um Ul Wara, Usha Tejwaney, Vikash Kumar Journal of International Medical Research.2023;[Epub] CrossRef
Association between PNPLA3 and TM6SF2 gene polymorphisms and non-alcoholic fatty liver disease patients in Kazakhstan Ainura Amirkulova, Gulmira Derbissalina, Valeriy Benberin, Nasrulla Shanazarov, Gulshara Abildinova, Doskhan Kozhakhmet, Helena Katchman Electronic Journal of General Medicine.2023; 20(6): em546. CrossRef
The empirical dietary inflammatory pattern score and the risk of nonalcoholic fatty liver disease and cirrhosis Maryam K. Ibrahim, Robert M. Wilechansky, Prasanna K. Challa, Xuehong Zhang, Edward Giovannucci, Meir Stampfer, Andrew T. Chan, Tracey G. Simon Hepatology Communications.2023;[Epub] CrossRef
Effect of spironolactone on pharmacological treatment of nonalcoholic fatty liver disease Apostolis PAPAEFTHYMIOU, Michael DOULBERIS, Kyriaki KARAFYLLIDOU, Eleftherios CHATZIMICHAEL, Georgia DERETZI, Aristomenis K. EXADAKTYLOS, Fotios SAMPSONAS, Athanasios GELASAKIS, Spyros I. PAPAMICHOS, Georgios KOTRONIS, Dimitra GIALAMPRINOU, Elisabeth VARD Minerva Endocrinology.2023;[Epub] CrossRef
The experience of the "Nicolae Malaxa" Clinical Hospital Bucharest, 2021-2022: non-alcoholic hepatic steatosis – etiological and risk profile Gabriela-Carmen Obilişteanu, Alexandru-Mihai Ştefănescu, Florin-Mihai Lungana, Nicolae Runcanu Medic.ro.2023; 5(155): 8. CrossRef
Molecular Docking Study of Phytosterols in Lygodium microphyllum Towards SIRT1 and AMPK, the in vitro Brine Shrimp Toxicity Test, and the Phenols and Sterols Levels in the Extract Putri Anggreini, Hadi Kuncoro, Sri Sumiwi, Jutti Levita Journal of Experimental Pharmacology.2023; Volume 15: 513. CrossRef
Both full length‐cholesteryl ester transfer protein and exon 9‐deleted cholesteryl ester transfer protein promote triacylglycerol storage in cultured hepatocytes Yan Liu, Daniel Mihna, Lahoucine Izem, Richard E. Morton Lipids.2022; 57(1): 69. CrossRef
Red meat consumption, obesity, and the risk of nonalcoholic fatty liver disease among women: Evidence from mediation analysis Mi Na Kim, Chun-Han Lo, Kathleen E. Corey, Xiao Luo, Lu Long, Xuehong Zhang, Andrew T. Chan, Tracey G. Simon Clinical Nutrition.2022; 41(2): 356. CrossRef
Advanced liver fibrosis measured by transient elastography predicts chronic kidney disease development in individuals with non-alcoholic fatty liver disease Chan-Young Jung, Geun Woo Ryu, Hyung Woo Kim, Sang Hoon Ahn, Seung Up Kim, Beom Seok Kim Diabetologia.2022; 65(3): 518. CrossRef
Long-term surgical outcomes of Non alcoholic fatty liver disease associated hepatocellular carcinoma Mizelle D'Silva, Jai Young Cho, Ho-Seong Han, Yoo-Seok Yoon, Hae Won Lee, Jun Suh Lee, Boram Lee, Moonhwan Kim Surgical Oncology.2022; 41: 101730. CrossRef
MRE-based NASH score for diagnosis of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease Young-Sun Lee, Ji Eun Lee, Hyon-Seung Yi, Young Kul Jung, Dae Won Jun, Ji Hoon Kim, Yeon Seok Seo, Hyung Joon Yim, Baek-hui Kim, Jeong Woo Kim, Chang Hee Lee, Jong Eun Yeon, Juneyoung Lee, Soon Ho Um, Kwan Soo Byun Hepatology International.2022; 16(2): 316. CrossRef
DNA Methylation Patterns According to Fatty Liver Index and Longitudinal Changes from the Korean Genome and Epidemiology Study (KoGES) Young Kyung Ko, Hayeon Kim, Yoonseok Lee, Young-Sun Lee, Jeong-An Gim Current Issues in Molecular Biology.2022; 44(3): 1149. CrossRef
Cardiovascular Risk Is Elevated in Lean Subjects with Nonalcoholic Fatty Liver Disease Yuna Kim, Eugene Han, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Mi Kyung Kim, Hye Soon Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Yong-ho Lee, Seung Up Kim Gut and Liver.2022; 16(2): 290. CrossRef
Exercise reduces the risk of chronic kidney disease in individuals with nonalcoholic fatty liver disease: A nationwide cohort study Chan-Young Jung, Ho Soo Chun, Minjong Lee, Hee Byung Koh, Keun Hyung Park, Young Su Joo, Hyung Woo Kim, Sang Hoon Ahn, Jung Tak Park, Seung Up Kim Diabetes & Metabolism.2022; 48(5): 101362. CrossRef
Tenofovir alafenamide alleviates nonalcoholic steatohepatitis in mice by blocking the phosphorylation of AKT in intrahepatic mononuclear phagocytes Pu Reun Roh, Sung Min Kim, Byung-Yoon Kang, Kyoung Do Mun, Jong Geun Park, Min Woo Kang, Wonhee Hur, Ji Won Han, Heechul Nam, Seung Kew Yoon, Pil Soo Sung Biomedicine & Pharmacotherapy.2022; 156: 113952. CrossRef
Environmental exposure to organophosphate esters and suspected non-alcoholic fatty liver disease among US adults: A mixture analysis Haisheng Chai, Weiye Hu, Yaoyao Dai, Xiaohan Zhu, Ping'an Qian, Junfeng Zhu Frontiers in Public Health.2022;[Epub] CrossRef
A Nomogram Based on Preoperative Lab Tests, BMI, ICG-R15, and EHBF for the Prediction of Post-Hepatectomy Liver Failure in Patients with Hepatocellular Carcinoma Deyao Zhang, Yangxun Pan, Zhenyun Yang, Huilan Zeng, Xin Wang, Jinbin Chen, Juncheng Wang, Yaojun Zhang, Zhongguo Zhou, Minshan Chen, Dandan Hu Journal of Clinical Medicine.2022; 12(1): 324. CrossRef
Association between depression and nonalcoholic fatty liver disease: Contributions of insulin resistance and inflammation Ju Won Lee, Seung Ha Park Journal of Affective Disorders.2021; 278: 259. CrossRef
Evolution of liver fibrosis and steatosis markers in patients with type 2 diabetes after metformin treatment for 2 years Hye Won Lee, Jae Seung Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim Journal of Diabetes and its Complications.2021; 35(1): 107747. CrossRef
Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: Histological perspective Gwyneth Soon, Aileen Wee Clinical and Molecular Hepatology.2021; 27(1): 44. CrossRef
Association between the severity of liver fibrosis and cardiovascular outcomes in patients with type 2 diabetes Ho Soo Chun, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Yong‐Ho Lee, Young Dae Kim, Seung Up Kim Journal of Gastroenterology and Hepatology.2021; 36(6): 1703. CrossRef
From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple? Seong Hee Kang, Yuri Cho, Soung Won Jeong, Seung Up Kim, Jin-Woo Lee Clinical and Molecular Hepatology.2021; 27(2): 257. CrossRef
Body weight variability and the risk of cardiovascular outcomes in patients with nonalcoholic fatty liver disease Mi Na Kim, Kyungdo Han, Juhwan Yoo, Yeonjung Ha, Young Eun Chon, Ju Ho Lee, Tracey G. Simon, Andrew T. Chan, Seong Gyu Hwang Scientific Reports.2021;[Epub] CrossRef
Hepatic Steatosis Index in the Detection of Fatty Liver in Patients with Chronic Hepatitis B Receiving Antiviral Therapy Jin Won Chang, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Seung Up Kim Gut and Liver.2021; 15(1): 117. CrossRef
Clinical implications of renin–angiotensin system inhibitors for development and progression of non-alcoholic fatty liver disease Kwang Min Kim, Ji-Hye Roh, Sangjin Lee, Jeong-Hyun Yoon Scientific Reports.2021;[Epub] CrossRef
Nonalcoholic Fatty Liver Disease: A Global Perspective Wei-Kei Wong, Wah-Kheong Chan Clinical Therapeutics.2021; 43(3): 473. CrossRef
Association of Skeletal Muscle and Adipose Tissue Distribution with Histologic Severity of Non-Alcoholic Fatty Liver Min-Kyu Kang, Jung-Hun Baek, Young-Oh Kweon, Won-Young Tak, Se-Young Jang, Yu-Rim Lee, Keun Hur, Gyeonghwa Kim, Hye-Won Lee, Man-Hoon Han, Joon-Hyuk Choi, Soo-Young Park, Jung-Gil Park Diagnostics.2021; 11(6): 1061. CrossRef
Circulating miRNA is a useful diagnostic biomarker for nonalcoholic steatohepatitis in nonalcoholic fatty liver disease Tae Hyung Kim, Yoonseok Lee, Young-Sun Lee, Jeong-An Gim, Eunjung Ko, Sun Young Yim, Young Kul Jung, SeongHee Kang, Moon Young Kim, Hayeon Kim, Baek-hui Kim, Ji Hoon Kim, Yeon Seok Seo, Hyung Joon Yim, Jong Eun Yeon, Soon Ho Um, Kwan Soo Byun Scientific Reports.2021;[Epub] CrossRef
Inhaled exposure to air fresheners aggravated liver injury in a murine model of nonalcoholic fatty acid liver disease Sanghwa Kim, Ah Young Lee, Myung-Haing Cho Heliyon.2021; 7(3): e06452. CrossRef
Low Skeletal Muscle Mass Is a Risk Factor for Subclinical Atherosclerosis in Patients with Nonalcoholic Fatty Liver Disease Min-Kyu Kang, Jung-Gil Park Diagnostics.2021; 11(5): 854. CrossRef
Association between telomere length and hepatic fibrosis in non-alcoholic fatty liver disease Hee Kyung Shin, Jeong Hwan Park, Jung Hwan Yu, Young-Joo Jin, Young Ju Suh, Jin-Woo Lee, Won Kim Scientific Reports.2021;[Epub] CrossRef
Metabolic disease as a risk of hepatocellular carcinoma Naoshi Nishida Clinical and Molecular Hepatology.2021; 27(1): 87. CrossRef
Evaluation of the severity of nonalcoholic fatty liver disease through analysis of serum exosomal miRNA expression Jeong-An Gim, Soo Min Bang, Young-Sun Lee, Yoonseok Lee, Sun Young Yim, Young Kul Jung, Hayeon Kim, Baek-Hui Kim, Ji Hoon Kim, Yeon Seok Seo, Hyung Joon Yim, Jong Eun Yeon, Soon Ho Um, Kwan Soo Byun, Matias A. Avila PLOS ONE.2021; 16(8): e0255822. CrossRef
Liver stiffness by magnetic resonance elastography is associated with increased risk of cardiovascular disease in patients with non‐alcoholic fatty liver disease Jung Gil Park, Jinho Jung, Kritin K. Verma, Min Kyu Kang, Egbert Madamba, Scarlett Lopez, Aed Qas Yonan, Amy Liu, Ricki Bettencourt, Claude Sirlin, Rohit Loomba Alimentary Pharmacology & Therapeutics.2021; 53(9): 1030. CrossRef
Systematic review with meta‐analysis: bariatric surgery reduces the incidence of hepatocellular carcinoma Daryl Ramai, Jameel Singh, Janice Lester, Shahab R. Khan, Saurabh Chandan, Nicola Tartaglia, Antonio Ambrosi, Gaetano Serviddio, Antonio Facciorusso Alimentary Pharmacology & Therapeutics.2021; 53(9): 977. CrossRef
Lack of association between early menopause and non-alcoholic fatty liver disease in postmenopausal women S. H. Park, Y. E. Park, J. Lee, J. H. Choi, N. Y. Heo, J. Park, T. O. Kim, Y. S. Moon, H. K. Kim, H. J. Jang, H. Y. Park, C.-H. Jeong, K. T. Suk, D. J. Kim Climacteric.2020; 23(2): 173. CrossRef
Trends in the prevalence of chronic liver disease in the Korean adult population, 1998–2017 Seung Ha Park, Lindsay D. Plank, Ki Tae Suk, Yong Eun Park, Jin Lee, Joon Hyuk Choi, Nae Yun Heo, Jongha Park, Tae Oh Kim, Young Soo Moon, Hyun Kuk Kim, Hang Jea Jang, Ha Young Park, Dong Joon Kim Clinical and Molecular Hepatology.2020; 26(2): 209. CrossRef
Liver involvement in patients with Gaucher disease types I and III Rodrigo Tzovenos Starosta, Filippo Pinto e Vairo, Alícia Dorneles Dornelles, Suélen Porto Basgalupp, Marina Siebert, Maria Lúcia Alves Pedroso, Carlos Thadeu Schmidt Cerski, Mário Reis Álvares-da-Silva, Ida Vanessa Doederlein Schwartz Molecular Genetics and Metabolism Reports.2020; 22: 100564. CrossRef
Association of grip strength with non-alcoholic fatty liver disease: investigation of the roles of insulin resistance and inflammation as mediators Seung Ha Park, Dong Joon Kim, Lindsay D. Plank European Journal of Clinical Nutrition.2020; 74(10): 1401. CrossRef
Analysis of the dietary factors associated with suspected pediatric nonalcoholic fatty liver disease and potential liver fibrosis: Korean National Health and Nutrition Examination Survey 2014-2017 Mi Jin Kim, Kyung Jae Lee BMC Pediatrics.2020;[Epub] CrossRef
Multiparametric MR Is a Valuable Modality for Evaluating Disease Severity of Nonalcoholic Fatty Liver Disease Young-Sun Lee, Yang Jae Yoo, Young Kul Jung, Ji Hoon Kim, Yeon Seok Seo, Hyung Joon Yim, In Hee Kim, Soo Yeon Lee, Baek-Hui Kim, Jeong Woo Kim, Chang Hee Lee, Jong Eun Yeon, So Young Kwon, Soon Ho Um, Kwan Soo Byun Clinical and Translational Gastroenterology.2020; 11(4): e00157. CrossRef
Toll-like receptor 9, a possible blocker of non-alcoholic steatohepatitis? Soung Won Jeong Clinical and Molecular Hepatology.2020; 26(2): 185. CrossRef
Does limited expression of toll-like receptor 9 actually contribute to T cell activation and liver damage in nonalcoholic steatohepatitis? Hyuk Soo Eun Clinical and Molecular Hepatology.2020; 26(2): 236. CrossRef
Survival Outcomes According to Body Mass Index in Hepatocellular Carcinoma Patient: Analysis of Nationwide Cancer Registry Database Boram Cha, Jung Hwan Yu, Young-Joo Jin, Young Ju Suh, Jin-Woo Lee Scientific Reports.2020;[Epub] CrossRef
Clinical Patterns and Outcome of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease Seon Young Ahn, Suk Bae Kim, Il Han Song Canadian Journal of Gastroenterology and Hepatology.2020; 2020: 1. CrossRef
Clinical application of ultrasonography-guided percutaneous liver biopsy and its safety over 18 years Young Chang, Jun Il Kim, Bora Lee, Sang Gyune Kim, Min Jung Jung, Young Seok Kim, Soung Won Jeong, Jae Young Jang, Jeong-Ju Yoo Clinical and Molecular Hepatology.2020; 26(3): 318. CrossRef
Effects of a 6-month dietary-induced weight loss on erythrocyte membrane omega-3 fatty acids and hepatic status of subjects with nonalcoholic fatty liver disease: The Fatty Liver in Obesity study Bertha Araceli Marin-Alejandre, Itziar Abete, J. Ignacio Monreal, Mariana Elorz, Alberto Benito-Boillos, José Ignacio Herrero, Iñigo Navarro-Blasco, Josep A. Tur, Narcisa M. Bandarra, M. Angeles Zulet, J. Alfredo Martinez Journal of Clinical Lipidology.2020; 14(6): 837. CrossRef
Association between Atrial Fibrillation and Advanced Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease Min Kyu Kang, Jung Gil Park, Min Cheol Kim Yonsei Medical Journal.2020; 61(10): 860. CrossRef
Plasma Long Noncoding RNA LeXis is a Potential Diagnostic Marker for Non-Alcoholic Steatohepatitis Jung Gil Park, Gyeonghwa Kim, Se Young Jang, Yu Rim Lee, Eunhye Lee, Hye Won Lee, Man-Hoon Han, Jae Min Chun, Young Seok Han, Jun Sik Yoon, Min Kyu Kang, Young Oh Kweon, Won Young Tak, Soo Young Park, Keun Hur Life.2020; 10(10): 230. CrossRef
Weight gain during early adulthood, trajectory of body shape and the risk of nonalcoholic fatty liver disease: A prospective cohort study among women Mi Na Kim, Chun-Han Lo, Kathleen E. Corey, Po-Hong Liu, Wenjie Ma, Xuehong Zhang, Manol Jovani, Mingyang Song, Andrew T. Chan, Tracey G. Simon Metabolism.2020; 113: 154398. CrossRef
Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming Soung Won Jeong Diabetes & Metabolism Journal.2020; 44(5): 640. CrossRef
Sarcopenia Is a New Risk Factor of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Disease Min Kyu Kang, Kyeong Ok Kim, Min Cheol Kim, Jung Gil Park, Byung Ik Jang Digestive Diseases.2020; 38(6): 507. CrossRef
Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics Stergios A. Polyzos, Jannis Kountouras, Christos S. Mantzoros Metabolism.2019; 92: 82. CrossRef
Advancing the understanding of NAFLD to hepatocellular carcinoma development: From experimental models to humans Kan Chen, Jianbo Ma, Xiaoyuan Jia, Wen Ai, Zhongren Ma, Qiuwei Pan Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2019; 1871(1): 117. CrossRef
Editorial: effect of hepatic steatosis on liver stiffness in patients with chronic hepatitis B Beom Kyung Kim, Seung Up Kim Alimentary Pharmacology & Therapeutics.2019; 50(3): 333. CrossRef
Changes in real-life practice for hepatocellular carcinoma patients in the Republic of Korea over a 12-year period: A nationwide random sample study Beom Kyung Kim, Do Young Kim, Kwang-Hyub Han, Jinsil Seong, Jung Weon Lee PLOS ONE.2019; 14(10): e0223678. CrossRef
The evaluation of complications and mortality in non-alcoholic steatohepatitis-related cirrhosis Sezgin VATANSEVER, Zehra Betül PAKÖZ Marmara Medical Journal.2019; 32(1): 44. CrossRef
Goh Eun Chung, Eun Ju Cho, Jeong-Hoon Lee, Jeong-ju Yoo, Minjong Lee, Yuri Cho, Dong Hyeon Lee, Hwi Young Kim, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Fabien Zoulim
Clin Mol Hepatol 2017;23(1):66-73. Published online February 14, 2017
Background/Aims A recent study reported that entecavir had inferior efficacy in nucleos(t)ide analogue (NA)-experienced chronic hepatitis B (CHB) patients compared to NA-naïve patients. We sought to compare the efficacy of tenofovir disoproxil fumarate (TDF) in NA-experienced and NA-naïve CHB patients.
Methods We retrospectively enrolled 252 consecutive patients who had a serum hepatitis B virus (HBV) DNA level greater than 2,000 IU/mL at the initiation of TDF treatment and who received TDF for at least 6 months. Complete virologic suppression (CVS) was defined as undetectable serum HBV DNA. We generated a multivariate Cox proportional-hazard model to examine predictive factors that were independently associated with time to CVS.
Results The mean age of patients was 48.2 years, and the cohort included 181 NA-naïve patients and 71 NA-experienced patients. The median duration of TDF treatment was 14.4 (interquartile range, 9.5-17.8) months. A total of 167 (92.3%) of 181 NA-naïve patients achieved CVS, and 60 (84.5%) of 71 NA-exposed patients achieved CVS. Forty-nine (89.1%) of 55 patients who previously took an NA aside from adefovir and 11 (68.8%) of 16 adefovir-experienced patients achieved CVS. In multivariable analysis, previous adefovir exposure significantly influenced time to CVS (hazard ratio, 0.37; 95% confidence interval, 0.19-0.72; P=0.003), after adjusting for HBeAg positivity, baseline HBV DNA level and cirrhosis.
Conclusions Tenofovir had inferior efficacy in adefovir-experienced CHB patients compared to NA-naïve patients. The response of patients with previous adefovir exposure to TDF monotherapy should be monitored closely.
Citations
Citations to this article as recorded by
Tenofovir disoproxil fumarate for multiple nucleos(t)ide analogues treatment failure hepatitis B: Is monotherapy enough? Xieer Liang, Qing Xie, Jia Shang, Hong Tang, Min Xu, Qinghua Meng, Jiming Zhang, Pujun Gao, Jifang Sheng, Hao Wang, Jidong Jia, Guiqiang Wang, Shunquan Wu, Jingna Ping, Jinlin Hou Journal of Gastroenterology and Hepatology.2022; 37(3): 471. CrossRef
Switching from Tenofovir-Based Combination Therapy to Tenofovir Monotherapy in Multidrug-Experienced Chronic Hepatitis B Patients: a 5-Year Experience at Two Centers Jung Hun Kim, Jeong Han Kim, Won Hyeok Choe, So Young Kwon, Byung-chul Yoo, Eileen L. Yoon, Seong Hee Kang Antimicrobial Agents and Chemotherapy.2022;[Epub] CrossRef
Clinical effects of NTCP‐inhibitor myrcludex B Dongliang Cheng, Bing Han, Wei Zhang, Wei Wu Journal of Viral Hepatitis.2021; 28(6): 852. CrossRef
Effectiveness of tenofovir alafenamide for chronic hepatitis B patients with a poor response to the previously used nucleos(t)ide analogs Daiki Yamashige, Tetsuya Hosaka, Fumitaka Suzuki, Shunichiro Fujiyama, Yusuke Kawamura, Hitomi Sezaki, Norio Akuta, Masahiro Kobayashi, Yoshiyuki Suzuki, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Mariko Kobayashi, Hiromitsu Kumada Journal of Gastroenterology.2021; 56(11): 1008. CrossRef
Tenofovir‐based combination therapy or monotherapy for multidrug‐resistant chronic hepatitis B: Long‐term data from a multicenter cohort study Hyung Joon Yim, Sang Jun Suh, Young Kul Jung, Seong Gyu Hwang, Yeon Seok Seo, Soon Ho Um, Sae Hwan Lee, Young Seok Kim, Jae Young Jang, In Hee Kim, Hyoung Su Kim, Ji Hoon Kim, Young Sun Lee, Eileen L. Yoon, Myeong Jun Song, Jun Yong Park Journal of Viral Hepatitis.2020; 27(12): 1306. CrossRef
Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients Eun-Sook Park, Ah Ram Lee, Doo Hyun Kim, Jeong-Hoon Lee, Jeong-Ju Yoo, Sung Hyun Ahn, Heewoo Sim, Soree Park, Hong Seok Kang, Juhee Won, Yea Na Ha, Gu-Choul Shin, So Young Kwon, Yong Kwang Park, Byeong-Sun Choi, Yun Bin Lee, Nakcheol Jeong, Yohan An, Youn Journal of Hepatology.2019; 70(6): 1093. CrossRef
Treatment Outcome and Renal Safety of 3-Year Tenofovir Disoproxil Fumarate Therapy in Chronic Hepatitis B Patients with Preserved Glomerular Filtration Rate In Suk Min, Chang Hun Lee, Ik Sang Shin, Na Eun Lee, Hong Seon Son, Seung Bum Kim, Seung Young Seo, Seong Hun Kim, Sang Wook Kim, Seung Ok Lee, Soo Teik Lee, In Hee Kim Gut and Liver.2019; 13(1): 93. CrossRef
KASL clinical practice guidelines for management of chronic hepatitis B
Clinical and Molecular Hepatology.2019; 25(2): 93. CrossRef
Direct Detection of Drug-Resistant Hepatitis B Virus in Serum Using a Dendron-Modified Microarray Doo Hyun Kim, Hong Seok Kang, Seong-Suk Hur, Seobo Sim, Sung Hyun Ahn, Yong Kwang Park, Eun-Sook Park, Ah Ram Lee, Soree Park, So Young Kwon, Jeong-Hoon Lee, Kyun-Hwan Kim Gut and Liver.2018; 12(3): 331. CrossRef
Is Combination Antiviral Therapy Mandatory for Maintenance Therapy in Fully Suppressed Multidrug-Resistant Hepatitis B Patients? Sung Won Chung, Young Chang, Hyo Young Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim Gastroenterology Research and Practice.2018; 2018: 1. CrossRef
Is tenofovir monotherapy a sufficient defense line against multi-drug resistant hepatitis B virus? Yun Bin Lee, Jeong-Hoon Lee Clinical and Molecular Hepatology.2017; 23(3): 219. CrossRef
First
Prev
